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SUMMARY 
The vacuolar H+ -ATPase (v-ATPase) constitutes a crucial enzyme in regulating cellular pH and 
maintaining pH homeostasis to ensure essential cellular processes in view of processing, 
trafficking and degradation. Being involved in such indispensable mechanisms, deregulation of 
the proton translocating enzyme has been linked to diseases of the renal system, osteoclast 
dysfunction and cancer [1-3], when the tight control of the pH cannot be maintained. The v-
ATPase has thus been emphasized as potential drug target. The myxobacterial compound 
archazolid inhibits the v-ATPase in the low nanomolar range [4] and has further been evidenced 
to potently induce apoptotic mechanisms in tumor cells [5]. As promising agent for future anti-
cancer therapies it was of particular relevance to investigate whether archazolid also affects 
primary immune cells that are components of the tumor microenvironment. In this context, 
macrophages as representative cells of the innate and adaptive immune system were addressed in 
this work. Thus, several assays with macrophages differentiated from freshly isolated monocytes 
were performed. The ability of macrophages to polarize upon activating stimuli into the pro-
inflammatory but anti-tumoral M1 phenotype and the M2 phenotype with opposing properties [6] 
was further addressed in the investigation of archazolid. Especially concerning cancer occurrence 
the predominating macrophage subtype (i.e. M2) is significant for tumor development and disease 
progress. This is mainly attributable to a variety of mediators formed by macrophages dependent 
on their polarization [7]. This thesis comprises two parts, which focus on distinct groups of 
mediators and whether they are affected by archazolid. 
The first part concerns a selection of tumor-relevant pro- and anti-inflammatory cytokines, 
produced upon inflammatory stimuli by cells of the immune system, such as macrophages. Once 
released, they aim at the communication between these cells whereby they exhibit pro- or anti-
inflammatory potential. Signaling pathways, also studied in this work, regulate their formation and 
determine their time-dependent release [8]. Tumor necrosis factor (TNF)α belongs to the most 
prominent cytokines that was discovered about 50 years ago as inducer of malignant cell necrosis 
[9]. M1-like macrophages are an abundant source of TNFα which is further closely related to pro-
inflammatory events which limited the cytokine’s use in systemic administration to cancer patients 
although it can still be used when administered by a specific technique [10]. Archazolid elevated 
TNFα levels selectively in M1, attributable to a transcriptional induction, whereas M2 were not 
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affected. As underlying mechanism it could be established that archazolid affects the transcription 
factor nuclear factor kappa B (NF-κB). Thus, it was hypothesized that elevated TNFα levels 
induced by archazolid in M1 might exhibit cancer cell death inducible activity supporting the 
compound’s direct cytotoxic activities on cancer cells while sparing the host macrophages. 
The second part of this thesis approaches the modulation of the arachidonic acid (AA) cascade by 
archazolid, where in turn both pathways, lipoxygenase (LO) and cyclooxygenase (COX) pathway, 
were considered. The first route uses 5-LO to convert AA to leukotrienes (LT). LTs are potent 
lipid mediators that have originally been found to mediate the characteristic symptoms of diseases 
of the respiratory system like asthma, while their contribution to cardiovascular diseases (CVD), 
auto-immune diseases, and cancer have been established later [11]. 15-HETE, which is in turn 
metabolized into lipoxins, is another metabolite of AA formed by 15-LO. Contrarily to 5-LO 
products, 15-LO-derived mediators have been evidenced to be involved in the resolution of 
inflammation [12]. Archazolid was demonstrated to affect the LOs in a different manner, since 5-
LO product formation was inhibited in M1 and M2 while 15-HETE was increased only in M1. 
Although it was emphasized that archazolid seems to affect the enzymes directly, the distinct role 
of M1 and M2 in this context could only be elucidated partly. The COX-2 is another key enzyme 
in the AA metabolism converting the substrate into prostanoids, of which prostaglandin (PG)E2 is 
the most prominent representative. It mediates some of the characteristic symptoms of an acute 
inflammation, such as fever, pain, redness and swelling [13], but recently, it has also been 
identified to induce the resolution phase of inflammation due to its context dependent effects [14]. 
PGE2 is produced especially by M1-like macrophages in which PGE2 levels were elevated by 
archazolid due to an induction of COX-2 mRNA in M1 but not in M2. This led to the conclusion 
that the underlying mechanism is related to the transcriptional induction of TNFα. 
Together, it is notable that the v-ATPase inhibitor archazolid elevated the levels of the M1-related 
mediators TNFα and PGE2 selectively in M1, whereas they remained unaffected in M2. The LO 
pathway of M1 is modulated by archazolid in favor of the anti-inflammatory pro-resolving 
metabolite 15-HETE. The results of this thesis provide novel insights into the impact of v-ATPase 
inhibition on primary cells, they emphasize the advantage of investigating different macrophage 
phenotypes and elucidate the possibility of their specific manipulation. In particular, the results 
suggest that archazolid increases M1 specific properties that might potentiate the anti-tumoral 
activity of this v-ATPase inhibitor and links important roles of the V-ATPase in this context. 
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ZUSAMMENFASSUNG 
Die ATPase des Vakuolen-Typ (v-ATPase) stellt ein entscheidendes Enzym für die Regulierung 
des zellulären pH Wertes und die Aufrechterhaltung der pH Homöostase dar, wodurch 
grundlegende zelluläre Vorgänge, wie Prozessierung, Transport und Abbau gewährleistet werden 
[3]. Als Bestandteil dieser essentiellen Mechanismen kann eine Fehlfunktion dieses Enzyms zu 
Nierenerkrankungen, veränderter Osteoklastentätigkeit oder Krebs führen [1, 2], wenn die 
notwendige exakte Kontrolle des pH Wertes nicht mehr aufrechterhalten werden kann. Die V-
ATPase stellt aus diesem Grund ein mögliches Arzneistofftarget dar. Archazolid, eine 
ursprünglich aus Myxobakterien isolierte Verbindung, hemmt die V-ATPase im niederen 
nanomolaren Bereich [4] und wurde bereits als Substanz identifiziert, die die Apoptose in 
Tumorzellen potent zu induzieren vermag [5]. Da Archazolid eine vielversprechende Substanz für 
zukünftige Krebsbehandlungen darstellt, war die Untersuchung dieser Verbindung in Hinblick auf 
deren Einfluss auf primäre Immunzellen, die in der Tumormikroumgebung anzutreffen sind, von 
besonderem Interesse. Als repräsentative Vertreter der Immunzellen innerhalb der angeborenen 
und adaptiven Immunantwort wurden Makrophagen verwendet, die aus frisch isolierten 
Monozyten differenziert und für verschiedene Tests kultiviert wurden. Die Fähigkeit von 
Makrophagen in Folge entsprechender Stimuli zu entzündungsfördernden, Tumor bekämpfenden 
M1 Makrophagen oder M2 Makrophagen, die durch entgegengesetzte Eigenschaften 
charakterisiert sind, zu polarisieren [6] wurde ebenfalls in die Forschungsarbeit über Archazolid 
einbezogen. Der vorherrschende Makrophagen Subtyp (d.h. M2) ist besonders im Krebsgeschehen 
von zentraler Bedeutung, da er Tumorentwicklung und Krankheitsverlauf mitbestimmt. Dies ist 
vorwiegend auf die Vielfalt an Mediatoren zurückzuführen, die entsprechend des jeweiligen 
Polarisierungstyps von Makrophagen gebildet werden [7]. Die vorliegende Arbeit umfasst zwei 
Teile, welche jeweils unterschiedliche Gruppen dieser Mediatoren behandeln und deren 
Beeinflussung durch Archazolid darlegen. 
Der erste Teil bezieht sich auf eine Auswahl an Tumor-relevanten entzündungsfördernden und  
-hemmenden Zytokinen, die in Folge der Stimulation von Zellen des Immunsystems, wie 
beispielsweise Makrophagen, gebildet und freigesetzt werden. Freigesetzte Zytokine mit 
unterschiedlichem entzündungsförderndem oder -hemmendem Potential ermöglichen eine 
Kommunikation zwischen den Zellen. Verschiedene Signalwege, die ebenfalls in dieser Arbeit 
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untersucht wurden, regulieren dabei die Bildung und Freisetzung dieser Zytokine [8]. Tumor 
Nekrose Faktor (TNF)α ist eines der bekanntesten Zytokine, das vor ungefähr 50 Jahren durch 
seine Fähigkeit entdeckt wurde, Nekrose bösartiger Zellen hervorzurufen [9]. Makrophagen des 
M1 Phänotyps produzieren große Mengen an TNFα, welches allerdings auch eng mit 
entzündungsfördernden Prozessen verknüpft ist, die seine systemische Verabreichung an 
Krebspatienten limitierte. Wird jedoch eine spezielle Verabreichungstechnik angewandt, kann 
TNFα dennoch in Krebstherapien eingesetzt werden [10]. Durch Archazolid wurden die TNFα 
Level in M1 Makrophagen selektiv erhöht, was auf eine Induktion auf transkriptioneller Ebene 
zurückzuführen war, während M2 Makrophagen nicht beeinflusst wurden. Als zugrundeliegender 
Mechanismus hierfür wurde die Beeinflussung des Transkriptionsfaktors Nuclear Factor kappa B 
(NF-κB) durch Archazolid nachgewiesen. Dies führte zu der Hypothese, dass die durch Archazolid 
verursachten erhöhten TNFα Level in M1 den Tod von Krebszellen induzieren, dadurch die direkte 
Zelltoxizität von Archazolid auf Tumorzellen unterstützen, jedoch gleichzeitig die 
Makrophagenviabilität nicht beeinträchtigen sollten. 
Im zweiten Teil dieser Arbeit wird die Modulation der Arachidonsäure (AA)-Kaskade durch 
Archazolid behandelt, wobei sowohl der Lipoxygenase-(LO), als auch der Cyclooxygenase-
(COX) Weg berücksichtigt wurde. Dem ersten Weg folgend wird AA durch die 5-LO zu 
Leukotrienen (LT) umgesetzt. Bei diesen handelt es sich um potente Lipidmediatoren, die 
charakteristische Symptome von Atemwegserkrankungen, wie Asthma, hervorrufen. Ihre 
Beteiligung an kardiovaskulären Erkrankungen (CVD), Autoimmunerkrankungen und Krebs 
wurde erst später festgestellt [11]. 15-HETE stellt einen weiteren Metaboliten innerhalb der AA-
Kaskade dar, welcher durch die 15-LO gebildet und nachfolgend zu den Lipoxinen weiter 
umgesetzt wird. 15-LO Produkte wurden jedoch im Gegensatz zu den LT mit der Auflösung einer 
Entzündung in Verbindung gebracht [12]. Archazolid beeinflusste die beiden LOs in 
unterschiedlicher Weise: Mediatoren des 5-LO Weges wurden von Archazolid unabhängig des 
Makrophagen Subtyps inhibiert, während 15-HETE Level in M1 gesteigert wurden. Obwohl durch 
mehrere Experimente herausgestellt werden konnte, dass Archazolid einen direkten Einfluss auf 
die Enzyme ausübt, konnte die unterschiedliche Rolle von M1 und M2 in diesem Zusammenhang 
nur teilweise aufgeklärt werden. Die COX-2 stellt ein weiteres Schlüsselenzym der AA-Kaskade 
dar, welches das Substrat zu Prostanoiden umsetzt, unter denen Prostaglandin (PG)E2 der 
prominenteste Vertreter ist. PGE2 vermittelt einige der charakteristischen Symptome einer akuten 
Zusammenfassung 
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Entzündungsreaktion, zu denen Fieber, Schmerz, Rötung und Schwellung gehören [13], wobei 
kürzlich ebenso sein Beitrag zur Induktion der Auflösungsphase der Entzündung diskutiert wurde 
[14]. PGE2 wird vorwiegend vom M1 Phänotyp gebildet, in welchem eine Erhöhung der PGE2 
Level durch Archazolid aufgrund einer Induktion der COX-2 mRNA nachgewiesen werden 
konnte. Dies führte zu der Schlussfolgerung, dass die zugrundeliegenden Mechanismen denen 
entsprechen, die die transkriptionelle Induktion von TNFα verursachten. 
Zusammenfassend zeigte der V-ATPase Inhibitor Archazolid eine bemerkenswerte selektive 
Steigerung der M1-verwandten Mediatoren TNFα und PGE2 ausschließlich im M1 Makrophagen 
Phänotyp, während M2 Makrophagen unbeeinflusst blieben. Der Lipoxygenase-Weg wird durch 
Archazolid zugunsten des entzündungshemmenden und die Phase der Auflösung unterstützenden 
Mediators 15-HETE beeinflusst. Die in dieser Arbeit dargestellten Ergebnisse liefern somit neue 
Erkenntnisse über den Einfluss der V-ATPase Inhibition in Primärzellen, machen dabei einerseits 
die Notwendigkeit der Untersuchung verschiedener Makrophagen Phänotypen deutlich und 
offenbaren andererseits, dass deren spezifische Beeinflussung möglich ist. Im Speziellen deuten 
die Resultate darauf hin, dass Archazolid M1-spezifische Eigenschaften steigert, wodurch dessen 
anti-tumorale Aktivität potenziert werden könnte und neue Einsichten zur Rolle der v-ATPase 
offenbart werden. 
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1 INTRODUCTION 
1.1 Inflammation 
Inflammation is a physiological process closely connected to the innate immunity as it is an 
essential response of an organism to secure survival in case of injury or against invading pathogens 
that cause infection. Due to the conspicuousness of an inflammatory reaction, the five main 
symptoms have already been defined long time ago: redness, heat, swelling, pain and loss of 
function are the consequences of diverse mediators formed from the beginning of an inflammation. 
Whereas in non-infectious inflammation the triggers causing tissue injury are still incompletely 
understood, the molecular mechanisms of a bacterial, viral or parasitic elicited inflammatory 
response are well-characterized [15]. 
 Acute inflammation 
When the body is attacked by invading pathogens it will respond by an immediate immune 
reaction, the acute inflammation, to avoid infection and tissue injury and to maintain homeostasis. 
Due to the rapidity of this first defense system it is unspecific and consists of several events [16]. 
In case of a bacterial infection macrophages recognize foreign particles by specific receptors (see 
1.1.4) which lead to the production and delivery of inflammatory mediators, including lipid 
mediators, cytokines, and chemokines. Thereby, neutrophils are recruited to the site of 
inflammatory origin and become activated. Releasing toxic agents like reactive oxygen species 
(ROS) from their granules, they eliminate pathogens but can also damage host cells [17]. 
Additionally, monocytes enter the tissue and thereby differentiate into inflammatory macrophages. 
Furthermore, activation of the complement system supports the destruction of bacterial invaders 
by facilitating their phagocytosis and further chemoattraction of neutrophils. Delivery of nitric 
oxide (NO) and prostaglandins (PG) at the site of inflammation leads to vasodilatation, enhancing 
the release of soluble factors while evoking redness and warmth of the affected tissue. For the 
same purpose, leukotrienes (LT), histamine and other metabolites increase vascular permeability, 
thereby contributing to the formation of edema due to an opening of endothelial cell tight junctions 
[18, 19]. The common aspect of all these mechanisms is the elimination of the pathogen and 
protection of the host, avoiding infection and initiating repair systems. One of the most important 
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mechanisms beneath these, however, is to secure the termination of the inflammatory processes 
and to activate the resolution of inflammation before the host suffers from the inflammatory 
activities. The termination sequences are already activated shortly after the inflammatory response 
has begun. They include the shift from pro- to anti-inflammatory mediators, the cessation of 
neutrophil infiltration and recruitment to the inflamed tissue, the initiation of programmed cell 
death by apoptosis of neutrophils, and their engulfment by phagocytic macrophages [20]. This way 
the affected tissue returns to its pre-infected status. 
 Chronic inflammation 
Chronic inflammation arises from a persisting and non-resolving acute inflammation. While acute 
inflammation is self-limiting and thus represents the necessary and beneficial response of the 
immune system for protection against pathogens, the failure of initiating the resolution phase 
provokes a chronic inflammatory environment which damages the host [21]. The mechanisms 
which may lead to a prolonged inflammatory status are multifaceted and an exact identification is 
sometimes impossible due to functional interactions. Phagocytosis of apoptotic neutrophils by 
macrophages triggers the release of anti-inflammatory cytokines. Deficiency in this event leads to 
necrosis of neutrophils which elicits pro-inflammatory signals, similarly to that caused by 
microbial products [22]. Attenuation of the pro-inflammatory state of monocytes and macrophages 
constitutes another critical event. Phagocytosis of tissue debris by monocytes induces their 
phenotypic switch from pro- to anti-inflammatory and, furthermore, the release of anti-
inflammatory cytokines which suppress the activity of pro-inflammatory macrophages [23]. Too 
strong or too weak T-cell responses as well as an impaired function of T regulatory cells promote 
the prolongation of inflammation [22]. Apart from the cellular involvement, soluble factors, 
released from immune cells, determine the development of inflammation: Cytokines, ROS and 
reactive nitrogen species (RNS), and lipid mediators are, among others, involved in preservation 
or resolution of inflammation [17, 22]. Naturally, also the persistence of exogenous inflammatory 
stimuli in the form of toxins or antigens are essential events in chronification, even if this is not an 
indispensable requirement. Often, the inflammatory events themselves are harming the host [22]. 
Notably, inhibition of inflammation is not the key to return to homeostasis, although it improves 
the cardinal signs of acute inflammation. In fact, inhibition even prolongs the inflammatory status 
due to its resolution-impairing effect [24, 25]. 
Introduction 
 
3 
Ultimately, an inflammatory environment which persists a longer period of time facilitates the 
emergence of diverse diseases or, even if it is not their underlying reason, promotes disease 
progress by the given mechanisms [26, 27]. 
 Inflammation-related diseases 
If inflammation escapes from its protective function due to deficiencies of inflammation resolving 
mechanisms, therefore sliding into chronic inflammation, it is strongly associated with diverse 
diseases. Cardiovascular and renal diseases, type 2 diabetes, autoimmune diseases as rheumatoid 
arthritis, asthma, and cancer are, for instance, affected in their initiation and progression by a 
chronic inflammation [28].  
1.1.3.1 Cancer 
Long lasting inflammatory processes cause pathological changes and concerning cancer, can affect 
different phases of disease development: Tumorigenesis by survival mechanisms, including 
cellular transformation and escape from immune surveillance as well as tumor spread by invasion, 
angiogenesis and metastasis [26]. The link to chronic inflammation concerns many different types 
of cancer and for some of them the inflammatory stimulus responsible for the manifestation of the 
neoplasm is even known. Examples are lung carcinoma caused by bronchitis, colorectal carcinoma 
induced by inflammatory bowel diseases and bladder carcinoma triggered by cystitis [29]. The 
arising tumor microenvironment still shows strong similarities to the initial inflammatory site, 
where immigration of immune cells and the production of specific mediators are essential events 
[30]. However, the tumor enables its survival by changing the infiltrating immune cell status in 
favor of an anti-inflammatory and immune suppressive phenotype and therefor exploits the 
plasticity of many immune cells. Macrophages are influenced by the tumor to develop towards the 
tumor associated macrophages (TAM), promoting proliferation, angiogenesis, invasion, and 
metastasis by production of corresponding factors and enzymes [31] (see 1.2.1). Furthermore, 
dendritic cells (DC) are impeded to mature, thus preventing the activation of T-cells that trigger 
an anti-tumoral immune response [32]. T-cells themselves are induced to develop towards the 
immune suppressive type 2 phenotype, ineffective in fighting against the tumor. This illustrates 
that the tumor microenvironment is not lacking immune cells or inflammatory cytokines in 
general. Instead, it generates an anti-inflammatory, immune suppressive environment with their 
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help. This is supported by the finding that in some cancer patients a systemic inflammatory 
response seems to be impossible [31], thus shielding the tumor from an attack of the immune 
system. 
 Molecular signaling in bacteria-induced inflammation 
There are diverse signaling pathways leading to the formation of pro-inflammatory mediators. Of 
importance for the detection of bacterial inducers are the so-called Toll-like receptors (TLR), a 
family of transmembrane proteins pertaining to the signaling pattern recognition receptors (PRR). 
These are localized on immune cells, especially on antigen-presenting cells such as macrophages 
and play a major role by recognizing microbial components leading to the production of several 
effector molecules: transcription factors, cytokines (interleukin (IL)-1, IL-6, tumor necrosis factor 
(TNF)α), chemokines (monocyte chemotactic protein (MCP)-1, IL-8) and eicosanoids as part of 
the early immune reaction, causing themselves the induction of further mediators [15, 33]. In case 
of the gram-negative bacterial membrane component lipopolysaccharide (LPS), the detection 
occurs by TLR4 on macrophages leading to the activation of intracellular signaling cascades. The 
exact mechanism of detection starts with the LPS-binding protein (LBP), which transfers LPS 
monomers to the cluster of differentiation (CD) 14 receptor on the cell membrane. However, 
lacking a transmembrane domain, CD14 demands TLR4 and its associated myeloid differentiation 
protein (MD)-2 for transducing the LPS signal and thus activating one of the intracellular 
downstream cascades [34, 35]. 
1.1.4.1 Protein Kinases involved in LPS signaling and inflammation 
In response to LPS, mitogen activated protein kinases (MAPK) play a major role in transferring 
the inflammatory signal. Their signaling results in promotion of transcription factor expression 
and induced cytokine production. The classical activation of a MAPK is initiated by 
phosphorylation by a MAPK kinase (MEK), which is in turn activated by a MEK kinase (MEKK). 
Extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) belong to the 
most important MAPK involved in inflammation [36]. In this manner, ERK1/2 becomes activated 
by MEK1/2, p38 activity is regulated by MEK3/6, and JNK phosphorylation is performed by 
MEK4/7. The prominent involvement of these three kinases in the inflammatory response is, for 
instance, represented by their regulation of TNFα, the paragon of inflammatory cytokines [37]. 
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Whereas JNK is involved in TNFα transcription and translation [38] and p38 regulates TNFα 
mRNA in post-transcriptional processes, such as stability and translation [39-41], ERK affects the 
transport of the TNFα transcript from the nucleus to the cytoplasm [42]. However, besides TNFα, 
gene expression of many other inflammatory target proteins is induced [43, 44]. 
Apart from MAPK, the serine/threonine kinase Akt (also called protein kinase B/PKB), likewise 
activated upon TLR4 activation, is involved in the inflammatory occurrence [36]. Signaling of Akt 
proceeds via the phosphoinositide 3-kinase (PI3-K) pathway, which includes the 
phosphatidylinositol (3,4,5) triphosphate (PIP3) mediated translocation of Akt to the plasma 
membrane and activating phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) [45]. 
In this way, the transcription factor nuclear factor kappa B (NF-κB) becomes activated and thus 
contributes to the pro-inflammatory effects of Akt [46]. However, Akt is also implicated in anti-
inflammatory actions since it induces the LPS-stimulated production of IL-10 [47, 48]. 
Furthermore, elevated activity of Akt, for instance due to the repression of deactivating factors, 
has been observed in some types of tumors, leading to enhanced cancer cell survival and 
proliferation [49]. 
1.1.4.2 Transcription factors involved in inflammation 
Transcription factors are proteins with the ability to bind specific DNA sequences, thereby 
regulating the transcription of the appropriate target gene. Thus, they are essential for 
physiological processes, but equally important if deregulated mechanisms result in disease. 
Probably the most prominent transcription factor involved in inflammatory processes is NF-κB. 
NF-κB consists of a dimer of two of five possible mammalian subunits: NF-κB1 (p105, 
proteolytically processed to p50), NF-κB2 (p100, proteolytically processed to p52), RelA (p65), 
RelB, and c-Rel. The Rel homology domain (RHD) is the common structure of all these subunits 
and is responsible for DNA binding, dimerization, nuclear localization, and inhibitor of kappa B 
(IκB) binding [50]. The five Rel family members are expressed in every cell type and are able to 
affect a huge number of genes which enables NF-κB to possess a large variety of functions. 
However, it is especially of relevance when stress conditions demand rapid gene transcription 
since activation of NF-κB via the classical pathway up to DNA binding of the target gene occurs 
within minutes [50, 51]. The classical or so-called “canonical pathway” is activated upon 
stimulation with LPS or the cytokines IL-1 and TNF. Thus, the IκB kinase complex (IKK), 
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consisting of the IKKα, IKKβ, and IKKγ subunits, becomes activated by phosphorylating upstream 
kinases. IKKβ then phosphorylates the inhibitory NF-κB-binding protein IκBα, resulting in its 
ubiquitination and therefore proteasomal degradation. Free NF-κB is hence enabled to translocate 
into the nucleus, where it binds to the DNA for regulating the expression of the respective target 
genes [50]. Furthermore, there are several mechanisms to regulate NF-κB activity in strength and 
duration: phosphorylation at different sites of NF-κB subunits, hyperphosphorylation of IKK, 
processing of NF-κB precursors (p100 and p105) or induction of IκB synthesis. The specificity of 
NF-κB binding to special sites in the promotors of target genes is enabled by the distinct 
composition of NF-κB dimers [50-53]. The amount and diversity of NF-κB-regulated genes is a 
possible explanation for the different roles of this transcription factor in disease, especially in 
cancer [54, 55]. Several regulatory functions of NF-κB expose it as tumor promoting factor: NF-
κB regulates cell proliferation by stimulating cytokine and growth factor expression and affecting 
cell cycle proteins [54]. It regulates expression of chemokines and growth factors, promoting 
angiogenesis, and regulates the expression of adhesion molecules, facilitating invasion and 
metastasis [56]. Deregulation of NF-κB controlling mechanisms and therefore overexpression of 
constitutively activated NF-κB are present in many types of cancer [55]. Nevertheless, NF-κB also 
mediates indispensable functions of the immune system. It regulates the expression of cytokines, 
occupying a key function in innate immunity by interferon (IFN)-γ expression in T-cells, IL-6 
expression in B-cells, TNFα expression in macrophages, and IL-12 expression in dendritic cells. 
In addition, it promotes lymphocyte proliferation and cell survival, hematopoiesis as well as 
apoptosis [54]. Whether NF-κB expresses tumor promoting or suppressing functions depends on 
the conditions and cannot be predicted generally. 
Another class of transcription factors with diverse contribution to cancer development is the signal 
transducer and activator of transcription (STAT) family. There are seven STATs which exist as 
cytoplasmic transcription factors that become activated after recruitment to and phosphorylation 
by protein tyrosine kinases. The cytokine receptor-associated Janus activated kinases (Jak), growth 
factor receptors and cytoplasmic tyrosine kinases are able to phosphorylate STAT proteins. 
Activation of STAT results in translocation of dimerized STATs into the nucleus, where they 
regulate gene transcription after binding to their response elements in the target gene [57]. A large 
number of cytokine receptors, for instance IL-2, IL-4, IL-6, IL-12, IFN, and growth factors signal 
through the Jak/STAT pathway. Consequently, STATs are extensively involved in B-cell 
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development, T-cell stimulation, neutrophil function and macrophage activation [58] that explains 
their essential role in inflammation and immunity as well as related diseases in case of 
deregulation. Indeed, key functions of STAT1, STAT3, and STAT5 have been found in many 
types of cancer [59-61]. Physiologically activated STAT3 and STAT5 contribute to cell growth 
and proliferation and an aberrant activity is therefore not surprisingly involved in tumor growth, 
progression, cancer cell survival and chemoresistance mechanisms [59]. Additionally, elevated 
levels of phosphorylated STAT3 are characteristic for a tumor infiltrating M2 macrophage 
phenotype [62] (see 1.2.2). Contrarily, STAT1 is associated with growth inhibition, apoptosis 
induction and is, due to its activation by IFNs, essential for a functional immune system [59], 
according to their expression in the anti-tumoral M1 phenotype [62] (see 1.2.2). Whereas 
inhibition of STAT3 and STAT5 has already been found to be beneficial for an anti-tumor therapy, 
the overexpression of STAT1 found in some tumors is not yet completely understood but seems 
to be positive in anti-cancer treatments since it acts as a tumor suppressor [60, 61]. 
 Cytokines 
Cytokines belong to a group of small proteins, ranging in their molecular weight from 8 to 40,000 
Da, and are categorized according to their biological function (pro-/anti-inflammatory), since the 
most cells are able to synthesize and even respond to them [63]. Cytokines are produced and 
released upon inflammatory stimuli for the communication between cells and their common 
orchestration of an immune response [8]. Chemokines are even identifiable by their name 
(chemotactic cytokines) to be specialized in initiating chemotaxis and thereby enabling the 
communication between cells. However, not only the communication between host cells but also 
of malignant cells among themselves or to the host’s immune cells, affecting them in favor of 
malignant cell growth, are enabled by a number of cytokines. To the class of pro-inflammatory 
cytokines belong TNFα, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-8, and MCP-1 whereas IL-4, IL-10, 
IL-13, and transforming growth factor (TGF)-β are attributed to the anti-inflammatory cytokines 
[31, 63-65]. Nevertheless, a strict division into pro- and anti-inflammatory is not always possible, 
since their effects depend on the context [63]. Stimulation of production and release of cytokines 
as well as effective stop mechanisms for their formation have to be tightly controlled in a biological 
system. Hence, it is obvious that intracellular trafficking of cytokines follows diverse pathways, 
being an option to coordinate and regulate their formation and release [8]. 
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1.1.5.1 TNFα 
TNF was first identified in 1962 [66] and its activity demonstrated in 1975 [9] before 1985 two 
TNFs with 50% sequence homology were structurally identified and separated into TNFα and 
TNFβ [67]. The TNFs are mainly formed by monocytes/macrophages, B-, and T-lymphocytes, as 
they are physiologically responsible for the immunological host defense against microbial 
infections [68]. LPS belongs to one of the most potent inducers of TNFα production and regulates 
it at the transcriptional and translational level. [69]. According to the classic secretory pathway, 
the initially in the endoplasmic reticulum (ER) formed membrane associated precursor protein (26 
kDa) underlies further processing in the Golgi. Subsequently, TNFα is transported from the trans-
Golgi network (TGN) via recycling endosomes, after sorting from other cargo, to phagocytic cups 
at the membrane. There it is cleaved by matrix metalloproteinases (MMP) into the 17 kDa soluble 
protein prior to release [8, 68]. TNFα reaches maximum levels after its release within very short 
times compared to other cytokines, but likewise, there are effective mechanisms to eliminate 
circulating TNFα in short time periods to prevent pathological conditions. The pro-inflammatory 
and immunomodulatory effects of TNFα are mediated by two cell surface receptors, TNFR1 and 
TNFR2. In this way TNFα induces the production of further inflammatory cytokines and activates 
cells of the immune system. The main inflammatory events, however, are attributable to TNFα’s 
effects on endothelial cells, whereby leukocyte populations are attracted to the site of infection. 
Consequently, fever and tissue injury, cell proliferation, differentiation and apoptosis are directly 
and indirectly caused by TNFα [69, 70].  
TNFα was discovered as an endogenous agent that induces necrosis of malignant cells [9]. 
Accordingly, after isolation and purification, TNFα was used in a variety of anti-cancer studies 
[71-75]. Nevertheless, the effects of TNFα in cancer occurrence are paradoxical, even due to its 
undisputed role in inflammation [10, 76, 77]. However, there is evidence that several mechanisms 
both, directly and indirectly, contribute to the destruction of tumor cells by TNFα. Local injections 
into the tumor with high and continuous doses of TNFα are important for an effective treatment 
[74, 78]. Thus, growth inhibition of established tumors, necrosis and apoptosis, platelet adherence 
and therefore destruction of the tumors’s vasculature can be achieved. Potentiation of efficacy is 
possible by combination of TNFα with IFN-γ. Another possibility to further increase the cytotoxic 
effects of TNFα on tumor cells consists of its combination with the chemotherapeutics melphalan 
or doxorubicin [79]. Representing an effective immunostimulatory cytokine, it is not surprising 
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that TNFα additionally mediates its anti-tumoral effects by inducing T-cell mediated immunity 
and stimulated macrophage cytotoxicity against cancer cells [71, 76, 80]. 
 Eicosanoids in inflammation and resolution 
In addition to cytokines, eicosanoids are a class of mediators extensively involved in processes 
regulated by the immune system. Eicosanoids are omega-6 polyunsaturated fatty acid (PUFA) 
derived lipid mediators, including PG, thromboxanes, LTs, hydroperoxyeicosatetraenoic acids 
(HpETE), hydroxyeicosatetraenoic acids (HETE), and lipoxins. All eicosanoids contribute to the 
inflammatory occurrence, even though their effects are diverse [81]. 
1.1.6.1 Key enzymes in eicosanoid formation 
Eicosanoids arise from the ω-6 PUFA arachidonic acid (AA) which is incorporated into 
phospholipids of cell membranes and upon stimulation cleaved by phospholipases, predominantly 
by the cytosolic phospholipase A2 (cPLA2). AA can subsequently be metabolized via two different 
pathways, the cyclooxygenase (COX) or the lipoxygenase (LO) pathway, both of them using AA 
as substrate [82]. 
The integral membrane protein COX, located primarily at the ER and perinuclear regions, exists 
in two isoforms. COX-1 is constitutively expressed, whereas COX-2 expression is induced by 
stimulation. Both enzymes are composed of an amino-terminal epidermal growth factor (EGF)-
like domain, a membrane-binding domain, and a large catalytic domain, including the heme-
binding site at the C-terminal end. The sequence identity of COX-1 and COX-2 is about 60-65%. 
An important structural difference of both enzymes is the larger active site of COX-2 allowing its 
specific inhibition by bulky inhibitors [83]. Regulation of enzyme expression and therefore 
prostanoid formation occurs by transcription elements in the promoter regions of the two COX 
genes. Here, NF-κB, cAMP-responsive element (CRE) and enhancer box (E-box) are solely 
present in the COX-2 gene, being involved in the specific regulation of COX-2 mRNA expression 
[84, 85]. Glucocorticoids, inhibiting prostanoid formation, act partly by suppression of NF-κB 
dependent transcription [86, 87], whereas non-steroidal anti-inflammatory drugs (NSAIDs) 
suppress COX-2 NF-κB-independently [83]. 
5-Lipoxygenase (5-LO) is another key enzyme converting AA into bioactive lipid mediators. It is 
composed of an amino-terminal “C2-like” domain with binding sites for regulatory factors and a 
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catalytic domain with the non-heme catalytic iron [88]. 5-LO is, unlike other lipoxygenases, a 
tightly regulated enzyme and conversion of AA thus controlled by multiple mechanisms. Ca2+, 
phosphatidylcholine (PC), coactosin-like protein (CLP), and adenosine triphosphate (ATP) affect 
the activity of 5-LO via direct binding [89]. Ca2+ stimulates 5-LO activity, shown in vitro by Ca2+-
mobilizing ionophores as A23187, which results in abundant leukotriene formation [90]. PC is a 
membrane component and a further stimulating factor for 5-LO activity [91]. It directs the enzyme, 
especially in presence of Ca2+, to the nuclear envelope [92, 93]. The F-actin binding protein CLP 
stimulates Ca2+-induced 5-LO activity and additionally increases stimulatory effects of PC, 
similarly acting as scaffold for 5-LO [94]. Another 5-LO-stimulating factor with a direct binding 
site is ATP which is supposed to promote enzyme stability stronger than other nucleotides [95, 
96]. An indispensable requirement for substrate conversion by 5-LO is the redox status. 
Lipidhydroperoxides oxidize the inactive ferrous (Fe2+) form into the active ferric (Fe3+) form. The 
catalytic iron in the cytalytic domain is thus either electron donor or acceptor and holds the enzyme 
in an active or inactive state. Nevertheless, also external stimuli contribute to the activity of 5-LO. 
Signaling via the MAPK p38 and ERK1/2 increase leukotriene synthesis by phosphorylation on 
Ser271 and Ser663, respectively [89]. Phosphorylation on Ser523 by the serine/threonine kinase 
protein kinase A (PKA) results in an inactivation of 5-LO due to an impaired nuclear import [89, 
97]. Even inadequate substrate supply limits leukotriene formation, for instance caused by an 
impaired functioning of the AA releasing cPLA2 [98]. Likewise, the 5-LO activating protein 
(FLAP) is an essential protein of the membrane-associated proteins in eicosanoid and glutathione 
metabolism (MAPEG) family in intact cells, responsible for the transfer of cleaved AA to the 5-
LO. FLAP is crucial for 5-LO product formation as shown by inhibitor studies where leukotriene 
synthesis is significantly reduced by its inhibition [99]. 
Apart from 5-LO there are two other lipoxygenases, i.e., 12-LO and 15-LO, both members of the 
non-heme iron dioxygenase family converting AA into H(p)ETEs. 12-LO is separated into 
platelet-type and leukocyte-type, both forming 12-HETE [100]. Even 15-LO includes a 
reticulocyte-type (15-LOX-1) and an epidermis-type (15-LOX-2), converting AA into 15-HETE. 
The leukocyte-type 12-LO and the reticulocyte-type 15-LO share high sequence conservation, 
substrate specificity and enzyme kinetics and are therefore often referred to as 12/15-LO [101]. 
Besides translational and post-translational regulation, 15-LOX-1 can be transcriptionally 
regulated by the cytokines IL-4 and IL-13, that were found to induce 15-LOX-1 expression in 
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monocytes [102]. Due to 15-LOX-1 preferring linoleic acid as substrate, its main product is 13-
(S)-HODE. 15-LOX-2, different from 15-LOX-1 with respect to its unique tissue distribution and 
higher substrate specificity for AA leading to 15-HETE [103], is upregulated by inflammation-
related IFN-γ in human epidermal keratinocytes [104]. Thus, 15-LOX-2 expression predominates 
in the LPS/INF-γ primed M1 macrophage phenotype, whereas the IL-4-related M2 subtype mainly 
expresses 15-LOX-1 [105]. Both 15-LO subtypes, however, are reported to be tumor suppressing 
as low expression of 15-LOX-1 is connected to pancreatic carcinogenesis [106] and reduction of 
15-LOX-2 expression associated with prostate cancer [107]. 
1.1.6.2 PGE2 and other prostanoids 
COX-2 is a dual acting enzyme in converting its substrate. In the first step, AA is dioxygenated by 
the enzyme’s COX activity to PGG2 which is in the second step immediately reduced to PGH2 by 
the hydroperoxidase functionality of COX [85]. PGH2 serves then as starting point for further 
degradation by specific enzymes to PGE2, thromboxane (Tx)A2/B2, PGD2/15d-PGJ2, PGF2α, and 
PGI2, respectively, which are, except for the conversion to PGF2α, nonoxidative reactions [13] 
(Figure 1.1). PGE2 can be synthesized by three PGE synthases, namely the inducible microsomal 
PGE synthase-1, the microsomal PGE synthase-2, and the cytosolic PGE synthase and mediates 
its effects through the four G-protein coupled receptors (GPCR) EP1, EP2, EP3, and EP4 [13]. For 
a long time it has been known to be a key factor in acute inflammation eliciting typical signs of an 
inflammatory response: vasodilatation and increased vascular permeability are caused by PGE2 
together with other factors like histamine and bradykinin. This results in an increased blood flow 
into the affected tissue, becoming visible in redness and edemas. By interaction with central sites 
PGE2 leads to pain and fever [108]. However, it becomes more and more evident that PGE2 is 
further involved in the resolution of inflammation [14, 109, 110]. As shown by Serhan et al. [110] 
in a collagen-antibody induced arthritis (CAIA) model in mice lacking mPGES-1, reduced PGE2 
levels led to increased disease severity. This is caused by a raise in neutrophil recruitment to the 
inflamed tissue whereas macrophage recruitment, important for the elimination of apoptotic 
neutrophils, remains unaffected, therefore supposing a key role for PGE2 in neutrophil-mediated 
inflammation. Uptake of dying neutrophils by macrophages further contributes to the inhibition of 
pro-inflammatory cytokine release by the release of PGE2 together with platelet activating factor 
(PAF) and TGF-β [111]. Moreover, neutrophil engulfment by macrophages induces the switch of 
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their eicosanoid profile [112] towards the anti-inflammatory metabolites 15-HETE/lipoxins. Even 
in neutrophils a phenotypic switch can be induced by PGE2, as well as the production of enzymes 
forming anti-inflammatory and pro-resolving eicosanoids, an event also referred to as “lipid 
mediator class switching” [113]. In a recent study PGE2 was shown to mediate anti-inflammatory 
properties by a pleurisy-resolving effect in rats [114]. Likewise, another report proposed an anti-
inflammatory role of COX-2 in pleurisy of rats in the resolution phase, partly due to PGE2, but 
also induced by the COX-2 metabolites PGD2/15d-PGJ2 [25]. Like PGE2, PGD2 mediates pro- and 
anti-inflammatory effects [115] by its DP1 and DP2 GPCRs [108]. PGD2 promotes the induction 
of anti-inflammatory enzymes [113], and its dehydration product 15d-PGJ2 additionally acts 
regulatory concerning cytokine production and immune cell trafficking, especially via DP1 [116]. 
TxA2 and its stable but less bioactive hydrolysis product TxB2 bind to the TP receptor, expressed 
in platelets, endothelial cells, smooth muscles and other cells [117, 118]. There, they mediate 
vasoconstriction and platelet aggregation [119], explaining their role in cardiovascular diseases 
(CVD) [120] and atherosclerosis [121]. Whereas platelets with predominant expression of COX-
1 are the major source of TXA2, also macrophages synthesize abundant amounts of this metabolite, 
using both, COX-1 and COX-2 for biosynthesis [117]. The role of TxA2 in tumor development is 
controversially discussed, as TxA2 promotes the expression of adhesion molecules on the 
endothelium [122] and cell migration [123]. But it has both, promoting and inhibiting effects in 
angiogenesis [123, 124], probably due to the two splice variants of the TP receptor TPα and TPβ 
[117]. PGI2 represents a further metabolite of the COX-pathway, functioning via its IP receptor 
that acts opposing to TxA2: Vasodilation and platelet inhibition are the main effects of PGI2 [120]. 
However, PGI2 is rapidly metabolized non-enzymatically into the inactive 6-keto-PGF1α. [118]. 
PGF2α is formed from PGH2 by PGF synthases and binds the FP receptor, including two splice 
variants FPα and FPβ, thus especially mediating functions in the renal and female reproductive 
system [118]. Ultimately, mediators formed in the COX-pathway express diverse, sometimes 
overlapping but partially opposing physiological and pathological effects. 
1.1.6.3 Lipoxygenase products 
5-LO as well as cPLA2 are soluble enzymes that translocate to the nuclear membrane upon 
stimulation [125], where they fulfill different functions. The cPLA2 cleaves AA from 
phospholipids, which is transferred by FLAP to the 5-LO [126]. The 5-LO converts AA in a two-
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step reaction, where it holds two different enzyme functions (Figure 1.1). By its dioxygenase 
activity oxygen is inserted into AA leading to 5-HpETE. This first reaction is common for all 
lipoxygenases, except for the position of oxygen insertion which occurs at the carbon for which 
the lipoxygenase is named: C-5, C-12, or C-15. The second function is unique for 5-LO and 
consists in an LTA4 synthase activity. By this, 5-HpETE is transformed into the unstable epoxide 
LTA4, which is either hydrolyzed to LTB4 or converted by the LTC4-synthase to the cysteinyl LTs 
(cysLT), including LTC4, LTD4, and LTE4 [127]. Alternatively, non-enzymatic hydrolysis of 
LTA4 into LTB4-isomeric DiHETEs [128] or transformation into the two stereoisomers trans-
LTB4 and epi/trans-LTB4 are possible [129]. Glutathione peroxidases convert 5-HpETE into the 
corresponding alcohol 5-HETE [127]. LTB4 is a potent chemotactic agent for neutrophils, enabling 
their adhesion to the endothelium, extravasation, and degranulation causing the release of toxic 
mediators. It furthermore activates cells of the immune system such as monocytes/macrophages 
and lymphocytes. These effects are attributable to LTB4 binding to its GPCRs BLT1 and BLT2 
[130]. Even the peroxisome proliferator-activated receptor (PPAR)α was found to be activated by 
LTB4, though mediating anti-inflammatory effects [131]. The cysLTs, also called slow-reacting 
substances of anaphylaxis (SRS-A), mediate smooth muscle contraction of the airways and 
vascular permeability by their CysLT1 and CysLT2 receptors, playing a huge role in diseases of 
the respiratory system like asthma [132, 133]. Apart from 5-LO there is 12-LO producing 12-
H(p)ETE and 15-LO forming 15-(S)-H(p)ETE. 15-(S)-HETE acts as precursor for the 
production of the trihydroxytetraenes lipoxin (Lx)A4 and LxB4 [134] via the intermediate 
epoxytetraene, a reaction catalyzed by 5-LO [135]. Two other pathways are known to yield 
lipoxins in a transcellular manner. The first route uses leukocyte 5-LO to form LTA4, which is 
transformed by platelet-type 12-LO, owning a lipoxin synthase activity, into LxA4/B4. In a second 
pathway, aspirin provoked acetylation of COX-2 results in the synthesis of 15-(R)-HETE leading 
to 15-epi-lipoxins by 5-LO activity [135, 136]. Contrarily to the products of 5-LO that 
predominantly mediate pro-inflammatory events, 15-LO products possess several 
counterbalancing effects which contribute to limit the inflammatory response and to initiate the 
resolution phase [12]. 15-HETE inhibits neutrophil adhesion to endothelial cells and 
transmigration processes due to its esterification into neutrophil phospholipids, mainly into 
phosphatidylinositol (PI) involved in signal transduction processes. Thus, 15-HETE can 
furthermore act as stored precursor for lipoxin formation. Remodeling of neutrophil phospholipids 
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by 15-HETE causes affinity reduction of LTB4 to its receptors and impairs the production of 
second messengers. Interaction of neutrophils with endothelial membranes is thus disturbed and 
Figure 1.1: Eicosanoid biosynthesis. AA is starting point for both, COX-pathway (upper half) and LOX-pathway 
(lower half). Prostaglandins, prostacyclin, and thromboxanes are formed by two COX-catalyzed steps resulting in 
PGG2 and PGH2, respectively, followed by the activity of several specific synthases. Stereospecificity of the different 
LOX lead to H(p)ETEs, leukotrienes, and lipoxins. 
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might limit the neutrophil mediated inflammatory response [137, 138]. Lipoxins, belonging to the 
anti-inflammatory eicosanoids as well, interact with inflammation promoting properties of 
neutrophils, for instance by inhibiting leukotriene induced vascular permeability [139]. 
Additionally, they impair neutrophil recruitment and infiltration [24]. Instead, mononuclear cells 
are recruited by lipoxins to enable tissue repair [140] and phagocytosis of apoptotic neutrophils by 
macrophages [141, 142]. Thus, some LO products play key roles in inducing inflammation but 
others in initiating the resolution phase. 
1.2 Macrophages 
Macrophages derive from haematopoietic stem cells (HSC) in the bone marrow, therefore 
belonging to the mononuclear phagocyte system (MPS), which further consists of blood 
monocytes, DC and the myeloid progenitor cells [143]. The bone marrow progenitors develop 
stepwise to monoblasts, pro-monocytes and monocytes before they are released into the blood 
stream, where they circulate or differentiate into macrophages by migration into tissues [144]. 
Macrophages are found in nearly all tissues [145]. The heterogeneity of blood monocytes due to 
their developmental state, and the tissue, entered by monocytes and providing different 
microenvironmental conditions, determine the development of different macrophage phenotypes 
[146]. Consequently, these distinct macrophage populations possess diverse functions, which 
reflects their ability to adapt in their physiological roles to the microenvironment, a property also 
known as macrophage plasticity. Host defense, wound healing and immune regulation are the three 
main features connected to macrophage functions [144]. Macrophages are prominent phagocytic 
cells and clearing the tissue from cell debris or apoptotic cells is vital for the host. However, 
whereas an immune response is absent in the case of phagocytosis of senescent cells occurring in 
a healthy state, the elimination of cells that have undergone necrosis is detected by macrophages 
due to necrosis-related danger signals, resulting in a change of macrophage physiology and 
therefore in the production and release of pro-inflammatory mediators. Thus, the innate immune 
response is activated [147]. Due to the recognition of such danger signals by PRRs as TLR on 
macrophages [148], these cells are one of the first immune cells detecting possible threats for the 
host and initiating countermeasures. 
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 M1 and M2 polarization 
Due to their marked plasticity, macrophages are able to polarize into specific phenotypes 
dependent on the microenvironmental conditions which demand distinct macrophage functions. 
The polarization state of M1 and M2 represents two opposing phenotypes, so called according to 
the T helper (TH)1/TH2 classification and their distinct communication with macrophages [149]. 
M1 respond to stimuli originating from an IL-12-mediated TH1 response, such as IFN-γ, or to 
microbial products, such as LPS. These stimuli lead to the classically activated macrophages [150] 
(Figure 1.2). M1 possess several characteristics which discriminate them from the M2 polarized 
macrophages. M1 are a source of pro-inflammatory cytokines, including TNFα, IL-1β, IL-6, IL-
12, IL-15, and IL-18 [151, 152], as well as of chemokines (CCL15, CCL20, CXCL9, CXCL10, 
CXCL11) to regulate immune cell recruitment, especially of DC, neutral killer cells (NK), and T-
cells [7, 144]. Elevated expression of major histocompatibility complex (MHC)-II antigens and 
CD80/CD86 as costimulatory factors, enabling the M1 for an efficient antigen presentation [151, 
153, 154], enhanced endocytic functions, and the ability to effectively kill intracellular pathogens 
[151], are further specific qualities. The latter is attributable to the synthesis of ROS and NO by 
the inducible NO synthase (iNOS) [155], itself triggered by increased TNFα levels [152], as well 
as to the acidification of the phagosome and the impairment of nutrient provision for 
microorganisms [156]. By communication with T- and B-cells, M1 are strongly involved in 
triggering the immune response [150] and exhibit potential to destroy tumor cells [157]. 
M2, representing a more heterogeneous group than M1, are supposed to be subdivided dependent 
on the stimulus [150]: Whereas M2b are generated by stimulation with Fcγ receptors plus a TLR 
stimulus, M2c are obtained in presence of glucocorticoids, IL-10 or TGF-β. Alternatively activated 
macrophages, or M2a, are triggered by the TH2 cytokines IL-4 or IL-13, according to their cell-
cell interaction. Characteristic properties of M2a are the upregulation of the mannose receptor 
(CD206) [158] and other C-type lectins [150] as well as scavenger receptors as CD163 [159], 
participating in hemoglobin clearance, adhesion to endothelial cells, and tissue regeneration [160]. 
M2a have an anti-inflammatory cytokine profile, including IL-10 and TGF-β, whereas M1-related 
cytokines are downregulated [151]. Chemokines from M2a (CCL5, CCL16, CCL17, CCL18, 
CCL22, CCL24) recruit eosinophils, basophils and TH2 cells [7, 144, 150]. Besides other 
intracellular enzymes, arginase 1 is upregulated [159], leading, contrarily to M1 producing NO by 
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the arginine pathway, to the production of polyamine and proline implicated in cell growth and 
proliferation, collagen formation and tissue repair [161]. M2 are furthermore involved in tumor 
initiation, progression, and metastasis, due to malignant cells exploiting the M2 functions in favor 
of their own development [162]. 
 Role of M1 and M2 in cancer occurrence 
The role of macrophages in cancer is crucial but multifaceted due to their implication in tumor 
progression and metastasis [163] as “alternative activated” M2 on the one hand and the ability of 
M1 to eliminate tumor cells and metastases on the other [164]. However, both phenotypes cannot 
be separated completely regarding tumor development, since a phenotypic switch is central 
especially in inflammation-related cancer. Regarding different phases of tumor establishment, the 
Figure 1.2: Macrophage differentiation and polarization. In presence of M-CSF, LPS, and the TH1-cytokine IFN-γ, 
monocytes differentiate and polarize into M1 which are characterized by high microbicidal and immune stimulating 
activity and potent tumor cell cytotoxicity. Contrarily, M2a develop in presence of M-CSF and the TH2-cytokines 
IL-4 or IL-13. They possess anti-inflammatory and scavenging properties, enable tissue repair and promote tumor 
progression. Mo, monocytes; MΦ, unpolarized macrophages; NK, neutral killer cells; DC, dendritic cells; BG, 
basophil granulocytes; EG, eosinophil granulocytes. 
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M1 phenotype may facilitate initiation and promotion [165], if the conditions of a chronic 
inflammation are present [163] or host immune reactivity remains unresolved [29]. Pro-
inflammatory mediators, originally produced by M1 as a result of the immune response for 
microbial killing, facilitate the formation of mutations by oxygen and nitrogen species reacting 
with the DNA of epithelial cells [166] and even accumulation of mutations by the inhibition of the 
tumor suppressor p53 [167]. The cellular alterations lead to changes in the cellular cytokine 
expression profile [168]. Consequently, on the way to malignancy, the tumor affects the 
macrophage phenotype, educating it from M1 towards M2 [165], since the M1 related gene 
expression profile is obstructive or even destructive for the tumor’s growth in this stage. The 
quantity of tumor-associated macrophages exhibiting an M2 phenotype in the tumor 
microenvironment is visible in many types of cancer, often correlated with poor prognosis [169]. 
Recruitment of M2 to the tumor occurs by colony-stimulating factor (CSF)-1, able to promote 
malignancy by facilitating infiltration and behavior of TAMs and therefore metastasis [170]. CSF-
1 upregulates the expression of vascular endothelial growth factor (VEGF) in macrophages, which 
attracts those as well, and plays a key role in vascularization and angiogenic processes. 
Angiogenesis is an important feature for solid tumors concerning growth and metastasis, enabling 
the tumor’s nourishment and therefore survival. Apart from VEGF, there are some more factors 
expressed by M2, directly or indirectly promoting angiogenesis, proliferation and viability, 
including hypoxia, hypoxia inducible factor (HIF)2α [171], HIF1α, and IL-1 [172], as well as 
several growth factors [173]. By suppression of immune functions, namely antigen presentation, 
DC maturation or cytotoxic activities, the tumor ensures its survival [173-175]. Inhibition of NF-
κB signaling, therefore decreasing the levels of iNOS, TNFα and other cytokines represent such 
an immune modulating mechanism by promoting the M2 immune suppressing phenotype [176]. 
In fact, the tumor exploits physiological functions of M2 such as tissue repair, release of anti-
inflammatory cytokines and growth factors, as well as immune-suppression, and redirects them 
for the own survival and progression. Nevertheless, the cytokines present in the microenvironment 
secreted during infection, inflammation, and immunity can likewise act as inhibitors of tumor 
development and progression [168], recruiting and activating immune cells and initiating an 
effective immune response against the malignant cells. Accordingly, the detection of tumor cells 
by the innate and adaptive immune system through recognition of antigens present on cancer cells 
[168, 177] is crucial for the coordinated activation of elimination mechanisms by M1, DC, NK 
cells, T- and B-cells; a mechanism also known as cancer immunosurveillance [178]. In fact, intra-
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tumoral lymphocyte infiltrates have been linked to decreased metastasis and increased patient 
survival [179], whereas lymphocyte absence leads to higher tumor susceptibility [180]. 
Furthermore, IFN-γ, released from T-cells and M1, functions anti-tumoral, whereas deficiencies 
in IFN-γ or the IFN-γ receptor result in deregulated target-cell growth and apoptosis, increased 
angiogenesis, and impaired upregulation of MHC I expression in the tumor [180-182]. Moreover, 
IFN-γ has been shown to initiate a phenotypic switch from immunosuppressive M2 like TAMs 
into the immunostimulatory M1 phenotype, able to induce CD4+ T-cell proliferation, CD8+ T-cell 
cytotoxicity, accompanied by the reduction of pro-tumoral TAM mediators [183]. Initiating the 
phenotypic switch from M2 to M1, preventing the reverse case in the early phase of tumor 
development, as well as inhibiting monocytes/macrophages to develop towards M2 are promising 
concepts of anti-cancer therapy [157]. This is due to M1 being potent effector cells against cancer 
[184] by direct elimination through TNFα and NO as the main mediators [177]. Different methods 
targeting the immune cell function have been reported, all of them resulting in an induction of anti-
tumoral immune responses [157]: Inhibition of STAT6 [185] or STAT3 [186] results in enhanced 
immune cell function and reduced tumor growth and metastasis. Inhibition of the TAM-related 
stress protein legumain leads to a CD8+ T-cell mediated TAM reduction in the tumor 
microenvironment [187]. Src homology 2-containing inositol phosphatase-1 (SHIP1) expression 
was found to prevent M2 skewing [188], whereas conversely, treatment with the TLR9 ligand CpG 
combined with an IL-10 receptor antibody promotes the phenotypic switch from M2 to M1, 
triggering DC maturation and an anti-tumoral immune response [184, 189]. Restoring the host’s 
immunity is additionally beneficial for anti-cancer immunotherapies, supporting their efficiency 
by recovered antigen presenting functions of immune cells [190]. 
1.3 Vacuolar-type H+ -ATPase 
 Structure and function 
The vacuolar H+ -ATPases (v-ATPase) act as ATP driven proton pumps to acidify intracellular 
organelles and maintain pH homeostasis in all eukaryotic cells [191]. Operating by a rotary 
mechanism similar to other ATPases like the well-characterized F-ATPase [192], the v-ATPase 
was first identified as such in 1983 [193, 194]. The v-ATPase is composed of an ATP-hydrolytic 
domain (V1), oriented to the cytoplasmic membrane side, and a membrane-embedded proton-
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translocating domain (V0) (Figure 1.3). V1 contains eight subunits (A-H), where A and B, forming 
a hexamer, are responsible for ATP binding and hydrolysis, D and F belong to the central stalk 
that connects the V1 and V0 domain, and C, E, G, and H form the peripheral stalk. V0 consists of 
six proteolipid subunits (a, c, c’, c’’, d, e). Subunit d completes the central stalk, whereas subunit 
a is attributed to the peripheral stalk [1]. The three different c-subunits are hydrophobic proteins, 
arranged to a ring [195] that forms together with D, F, and d the rotary component of the pump, 
hereby causing an active proton transport. The peripheral stalk functions as a stator that fixes the 
ATP hydrolyzing hexamer and subunit a in their positions during rotation [1] (Figure 1.3). 
Regulatory mechanisms include the reversible dissociation and assembly of the V1 and V0 domain, 
where subunit d is implicated due to its connective position between the rotary V0 ring and the 
central stalk of V1. Furthermore, the regulation of efficiency of coupling the proton transport with 
ATP hydrolysis as well as the control of cellular localization and membrane expression of v-
ATPase belong to these mechanisms [1]. In some cells, including macrophages, the v-ATPase is 
located at the membrane of intracellular compartments (such as lysosomes, endosomes, vacuoles, 
secretory granules, Golgi) and additionally at the plasma membrane [196]. Due to the diversity of 
effects that protons can have on many proteins concerning their charge, stability, or conformation, 
the concentration of protons (pH) in cellular compartments is of particular importance and explains 
the variety of v-ATPase functions [197]. The proton pumping enzyme contributes to cellular 
processes such as membrane trafficking, protein degradation [198], bone resorption [199], sperm 
maturation [200], renal acidification [2], receptor-mediated endocytosis, prohormone processing 
and uptake/transport of small molecules [1]. 
Figure 1.3: Structure of the v-ATPase. The activity of the v-ATPase 
depends on the assembly of two main domains, the peripheral and ATP 
hydrolyzing V1 domain, including the subunits A, B ( yellow), D, F (orange), 
and the N-terminal part of a (grey), and the integral V0 domain, containing 
the subunits a, e (grey), c, c’, c’’, and d (blue). Subunits D, F, and d form 
the central stalk, which connects V1 to V0 and acts as a rotor by coupling 
the energy from ATP hydrolysis to the rotation of the proteolipid ring formed 
by the three c subunits. Subunits C, E, G, and H (green) have a stator 
function during rotation and proton translocation [1]. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell 
Biology 8, 917-929 copyright 2007. 
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 Inhibition of the v-ATPase by myxobacterial compounds 
Implicated in such a variety of cellular processes, a malfunction of v-ATPase leads to the 
disturbance of several vital cell functions and therefore to diseases. An interference with the v-
ATPase might thus be a possible intervention for the treatment of such diseases. In this field, 
bacteria were once found to be a source of metabolites able to selectively inhibit the v-ATPase, 
while other ATPases remain largely unaffected by these compounds. The first natural product in 
this context, named bafilomycin, was isolated in 1984 from Streptomyces griseus [201], a species 
belonging to the order actinomycetales that are aerobic and Gram-positive actinobacteria [202]. 
Bafilomycin was shown  to have cytotoxic activity against fungi, yeast, and Gram-positive bacteria 
[201]. Bowman et al. [203] identified bafilomycin, a 16-membered lactone ring (Figure 1.4), as 
first and relatively specific inhibitor of the v-ATPase with an activity in the nanomolar range. The 
binding site of this plecomacrolide is supposed to be at the c subunit of the v-ATPase [204]. Later, 
also myxobacteria that have a very distinct secondary metabolism, were found to produce 
biologically active natural products inhibiting the v-ATPase [205]. Myxobacteria are Gram-
negative δ-proteobacteria [205], strictly aerobic and with relatively large rod-shaped cells. They 
live typically in soil but also related habitats [206]. The apicularens, isolated from the 
myxobacteria Chondromyces robustus in 1998 by Kunze et al [207] and also produced by other 
myxobacteria species, were structurally identified as 10-membered macrolactone with a highly 
unsaturated enamide side chain [208] (Figure 1.4). These compounds are inactive against Gram-
negative and Gram-positive bacteria, as well as against several yeasts and fungi [207], but have 
cytotoxic activity in the nanomolar range against several human cancer cell lines [209]. 
Structurally related to the benzolactone enamides, the apicularens are v-ATPase inhibiting agents 
[210] with their binding site at the interface of subunit a and c of the v-ATPase [211]. Another 
group of myxobacterial products are the archazolids, isolated from Archangium gephyra, as the 
fourth group of compounds detected in these strains [4, 212]. The compounds have potent 
cytotoxic activity in the low nanomolar range against different cell lines [213]. Structurally 
characteristic for the archazolids is the 24-membered macrolactone ring with a thiazole side chain 
[212, 214] (Figure 1.4). Archazolid possesses high potency against isolated v-ATPase and does 
not influence F-ATPase or Na+/K+-ATPase by binding to the c subunit [210]. Today,  
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bafilomycin A1, apicularen A, and archazolid B, used for the experiments in this thesis, are 
accessible by total chemical synthesis [208, 215-217]. 
 Role of the v-ATPase in disease 
Due to its broad physiological contributions, the v-ATPase is involved in several pathological 
processes. For example, the v-ATPase is implicated in the entry of several viruses and toxins by 
acidic compartments into cells, when low pH mediates fusion of endosomal and microbial 
membrane, thus releasing the pathogen’s mRNA into the cytoplasm [218]. Deregulation of the v-
ATPase due to genetic defects in the a4 or B1 subunit can cause distal renal tubule acidosis by a 
dysfunction of the v-ATPase to secrete protons from the cytoplasm of intercalated cells into the 
lumen of the tubule [2]. Furthermore, osteoclasts need the H+-pumping v-ATPase for bone 
resorption during bone remodeling. Genetic defects of the v-ATPase a3 subunit followed by 
deficient proton provision lead to osteopetrosis [219]. Moreover, the v-ATPase is extensively 
involved in tumor promotion. Many types of cancer have been shown to overexpress v-ATPase 
[220, 221] since elevated cytoplasmic pH promotes tumor cell growth whereas low pH in the 
extracellular environment facilitates invasiveness of cancer cells [222]. An acidic tumor 
Figure 1.4: Chemical structure of bafilomycin A1 (A), apicularen A (B), and archazolid B (C) 
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environment increases the release and activity of lysosomal proteolytic enzymes such as cathepsins 
and the activation of matrix metalloproteinases (MMP), responsible for the degradation of the 
extracellular matrix that is a requirement for a tumor to metastasize [223]. Accordingly, it has been 
shown by Sennoune et al that highly metastatic cancer cell lines have a higher expression of plasma 
membrane v-ATPase compared to poorly metastatic cell lines [221]. Metastatic activity could be 
further decreased by treatment with the v-ATPase inhibitor archazolid [223]. The marked 
expression of the v-ATPase at the plasma membrane is also important for microvascular 
endothelial cells involved in angiogenesis because too acidic environment impairs the migratory 
activity of these cells, which use the v-ATPase to regulate their cytosolic pH [224]. Exposure of 
normal cells to a persistent acidic environment usually induces apoptosis but tumor cells exploit 
an acidic pH for the survival mechanisms described above. Due to the common ability of cancer 
cells to circumvent apoptosis, the induction of programmed cell death of tumor cells by v-ATPase 
inhibition is a useful strategy to reduce tumor growth [5, 225, 226]. The use of v-ATPase inhibitors 
has also been beneficial in drug-resistant tumor cells that overexpress this proton pump [220, 225, 
227]. 
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2 AIM OF THE THESIS 
Persistent inflammatory processes have been identified to increase the risk for the development of 
solid tumors [29]. One of the main properties of the tumor microenvironment is an acidic pH for 
optimal activity of many tumor promoting factors, maintained by the activity of an overexpressed 
v-ATPase, pumping protons into cellular organelles and the extracellular space [228]. By specific 
inhibition of the v-ATPase, the myxobacterial compound archazolid B exhibits potent cytotoxic 
activity against several cancer cell lines [5, 222, 229]. However, only little is known about the 
effects of v-ATPase inhibitors on primary human cells, even though this constitutes a stringently 
required knowledge with respect to the treatment of cancer patients. Since the v-ATPase supports 
various vital physiological processes, it is important to investigate if v-ATPase inhibition impairs 
the viability of primary human cells. Immune cells, representing an essential part of the innate and 
adaptive immune system, are important effectors in cancer immunosurveillance [230, 231]. 
Nevertheless, immune cells possess different faces in regard to cancer development depending on 
the stimuli they are exposed to [230]. The polarization of macrophages into M1 and M2 represents 
such an opposing phenotypic development, since M1 exhibit cancer cell cytotoxicity while M2 
which predominate in tumor infiltrates (TAM) promote malignant cell growth [157]. Concerning 
inflammation-related cancer, several key elements have been identified to contribute to cancer 
occurrence in a multifaceted manner [26]. On this basis, it was the aim of this study to investigate 
whether or not archazolid B affects human monocyte-derived macrophages and if the polarization 
state of macrophages is of importance in this connection. Regarding this, the focus of investigation 
was on some of the reported key functionalities as enzyme regulation, cytokine release and 
transcription factor expression. It was further of relevance to reveal the biochemical mechanisms 
underlying the interference of archazolid B with these key factors. 
 
Materials and Methods 
 
25 
3 MATERIALS AND METHODS 
3.1 Materials 
Chemicals  
[3H]-arachidonic acid BIOTREND Chemikalien GmbH, Köln, Germany 
Acetic acid Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Acetonitrile Thermo Fisher Scientific Inc., MA 
Ammonium chloride Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Arachidonic acid Cayman Chemical, MI 
BCECF-AM Life Technologies/Thermo Fisher Scientific Inc., MA 
Biotase Biochrom GmbH, Berlin, Germany 
Bromphenol blue Merck KGaA, Darmstadt, Germany 
BSA Applichem GmbH, Darmstadt, Germany 
BSA, fatty acid free Sigma-Aldrich Inc., Deisenhofen, Germany 
Ca2+-Ionophor A23187 Cayman Chemical, MI 
CaCl2 Applichem GmbH, Darmstadt, Germany 
D’PBS SERVA Electrophoresis GmbH, Heidelberg, Germany 
DAPI Sigma-Aldrich Inc., Deisenhofen, Germany 
DCFH-DA Sigma-Aldrich Inc., Deisenhofen, Germany 
Dextran Sigma-Aldrich Inc., Deisenhofen, Germany 
DMEM (high glucose) Biochrom GmbH, Berlin, Germany 
DMSO Merck KGaA, Darmstadt, Germany 
EDTA Applichem GmbH, Darmstadt, Germany 
FCS PAA/GE Healthcare Europe GmbH, Freiburg, Germany 
FITC Thermo Fisher Scientific Inc., MA 
FITC-dextran Sigma-Aldrich Inc., Deisenhofen, Germany 
Formic acid Sigma-Aldrich Inc., Deisenhofen, Germany 
Glucose Applichem GmbH, Darmstadt, Germany 
Glycerole Caesar & Loretz GmbH, Hilden, Germany 
Glycine Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
HBSS Life Technologies/Thermo Fisher Scientific Inc., MA 
HCl Grüssing GmbH, Filsum, Germany 
HEPES Thermo Fisher Scientific Inc., MA 
Human serum Lonza Group AG, Basel, Switzerland 
IFN-γ PeproTech GmbH, Hamburg, Germany 
IL-4 PeproTech GmbH, Hamburg, Germany 
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KCl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
KH2PO4 Sigma-Aldrich Inc., Deisenhofen, Germany 
Leupeptin Sigma-Aldrich Inc., Deisenhofen, Germany 
L-glutamine Biochrom GmbH, Berlin, Germany 
Low fat powdered milk  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
LPS Sigma-Aldrich Inc., Deisenhofen, Germany 
LSC fluid Rotiszint® eco plus Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
LSM 1077 PAA/GE Healthcare Europe GmbH, Freiburg, Germany 
LysoTracker Red DND-99 Life Technologies/Thermo Fisher Scientific Inc., MA 
Methanol HPLC grade Merck KGaA, Darmstadt, Germany 
MgCl2 Merck KGaA, Darmstadt, Germany 
MgSO4 Applichem GmbH, Darmstadt, Germany 
Mowiol Life Technologies/Thermo Fisher Scientific Inc., MA 
MTT Sigma-Aldrich Inc., Deisenhofen, Germany 
Na2HCO3 Applichem GmbH, Darmstadt, Germany 
Na3VO4 Applichem GmbH, Darmstadt, Germany 
Na4P2O7 Sigma-Aldrich Inc., Deisenhofen, Germany 
NaCl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
NaF Applichem GmbH, Darmstadt, Germany 
NaH2PO4 Sigma-Aldrich Inc., Deisenhofen, Germany 
Nigericin Enzo Life Sciences Inc., NY 
Non-immune goat serum Life Technologies/Thermo Fisher Scientific Inc., MA 
Nonidet P40 Applichem GmbH, Darmstadt, Germany 
n-propyl gallate Sigma-Aldrich Inc., Deisenhofen, Germany 
Paraformaldehyde Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Penicillin-streptomycin 
solution Biochrom GmbH, Berlin, Germany 
peqGOLD IV protein marker peqLab Biotechnology GmbH, Erlangen, Germany 
PGB1 Biomol GmbH, Hamburg, Germany 
PMSF Sigma-Aldrich Inc., Deisenhofen, Germany 
Ponceau Sigma-Aldrich Inc., Deisenhofen, Germany 
rhM-CSF Cell Guidance Systems Ltd, Cambridge, UK 
RPMI 1640 Sigma-Aldrich Inc., Deisenhofen, Germany 
SDS Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Staurosporine Merck KGaA, Darmstadt, Germany 
STI Sigma-Aldrich Inc., Deisenhofen, Germany 
sucrose Applichem GmbH, Darmstadt, Germany 
Thiomersal Sigma-Aldrich Inc., Deisenhofen, Germany 
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Trifluoro acetic acid Applichem GmbH, Darmstadt, Germany 
Tris Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
TritonX100 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Trypan blue Sigma-Aldrich Inc., Deisenhofen, Germany 
Trypsin-EDTA Thermo Fisher Scientific Inc., MA 
Tween®20 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Zymosan A Sigma-Aldrich Inc., Deisenhofen, Germany 
β-glycerophosphate Sigma-Aldrich Inc., Deisenhofen, Germany 
β-mercaptoethanol Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
  
Compounds  
Actinomycin D Cayman Chemical, MI 
Ammonium chloride Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Apicularen A Prof. Menche, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany 
Archazolid B Prof. Menche, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany 
Bafilomycin A1 Sigma-Aldrich Inc., Deisenhofen, Germany 
BWA4C Sigma-Aldrich Inc., Deisenhofen, Germany 
Chloroquine Sigma-Aldrich Inc., Deisenhofen, Germany 
Cytochalasin B Enzo Life Sciences Inc., NY 
Dexamethasone Sigma-Aldrich Inc., Deisenhofen, Germany 
DPI Sigma-Aldrich Inc., Deisenhofen, Germany 
Indometacin Sigma-Aldrich Inc., Deisenhofen, Germany 
LY294002 BIOZOL Diagnostica Vertrieb GmbH, Eching, Germany 
Parthenolide Sigma-Aldrich Inc., Deisenhofen, Germany 
RSC-3388 Merck KGaA, Darmstadt, Germany 
SB203580 Enzo Life Sciences Inc., NY 
SP600125 Enzo Life Sciences Inc., NY 
U0126 Enzo Life Sciences Inc., NY 
  
Primer  
B2M (forward and reverse) TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany 
COX-2 (forward and reverse) TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany 
IL-1β (forward and reverse) TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany 
TNFα (forward and reverse) TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany 
  
  
Materials and Methods 
 
28 
Primary antibodies  
ATP6V0A2 Abcam plc, Cambridge, UK 
β-actin Santa Cruz Biotechnology Inc., Heidelberg, Germany 
COX-2 Enzo Life Sciences Inc., NY 
GAPDH Santa Cruz Biotechnology, Heidelberg, Germany 
FLAP Abcam plc, Cambridge, UK 
5-LO Prof. Steinhilber, Goethe University, Frankfurt/Main, Germany 
IκBα Cell Signaling Technology Inc., MA 
phosphorylated IκB Cell Signaling Technology Inc., MA 
NF-κB p65 Cell Signaling Technology Inc., MA 
phosphorylated NFκB p65 Cell Signaling Technology Inc., MA 
Akt Cell Signaling Technology Inc., MA 
phosphorylated Akt Cell Signaling Technology Inc., MA 
MEK1/2 Cell Signaling Technology Inc., MA 
phosphorylated MEK1/2 Cell Signaling Technology Inc., MA 
phosphorylated MEK3/6 Cell Signaling Technology Inc., MA 
p38 Cell Signaling Technology Inc., MA 
phosphorylated p38 Cell Signaling Technology Inc., MA 
p44/42 Cell Signaling Technology Inc., MA 
phosphorylated p44/42 Cell Signaling Technology Inc., MA 
phosphorylated SAPK/JNK Cell Signaling Technology Inc., MA 
phosphorylated STAT1 Cell Signaling Technology Inc., MA 
phosphorylated STAT3 Cell Signaling Technology Inc., MA 
  
Secondary antibodies  
Alexa Fluor® 488  
goat anti-rabbit IgG 
Life Technologies/Thermo Fisher Scientific Inc., MA 
Alexa Fluor® 555  
goat anti-mouse IgG 
Life Technologies/Thermo Fisher Scientific Inc., MA 
IRDye 800CW LI-COR Biosciences Inc., Bad Homburg, Germany 
IRDye 680LT LI-COR Biosciences Inc., Bad Homburg, Germany 
  
Antibodies for ELISA  
Capture/detection antibodies R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany 
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Consumables  
Clean-Up® C18 columns United Chemical Technologies Inc., PA 
Glass bottom dishes MatTek Corporation, MA 
Glass coverslips Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Microscope slides Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Nitrocellulose membranes Amersham/GE Healthcare Europe GmbH, Freiburg, Germany 
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3.2 Methods 
 Cell isolation and cell culture 
3.2.1.1 Monocyte isolation from leukocyte concentrates 
Leukocyte concentrates from peripheral blood of healthy female human donors without an anti-
inflammatory medication for the last ten days were obtained from the Institute of Transfusion 
Medicine, University Hospital Jena, and prepared by centrifugation (4000 × g, 20 min, 20 °C). 
Buffy coat cell isolation was achieved by dextran sedimentation (5% dextran from Leukonostoc 
spp. (Mr = 500,000 g/mol) (w/v) in dulbecco’s phosphate buffered saline (D’PBS)) at room 
temperature. Different cell fractions from buffy coats were obtained by density centrifugation at 
400 × g/10 min/20 °C on lymphocyte separation medium (LSM) 1077 without brake (Heraeus 
Multifuge X3R Centrifuge, Thermo Scientific, MA). Peripheral blood mononuclear cells (PBMC), 
containing monocytes, T-, and B-lymphocytes, were isolated by two further centrifugation steps 
at 150 × g/10 min/4 °C and were resuspended in ice-cold D’PBS. Monocytes from PBMC fraction 
were isolated by adherence to culture flasks (2 × 107 cells/mL RPMI 1640 medium supplemented 
with 10% (v/v) heat-inactivated fetal calf serum (FCS), L-glutamine (2 mM), penicillin (100 
U/mL), and streptomycin (100 µg/mL)) for 1 h at 37 °C/5% CO2 as described [232]. 
3.2.1.2 Macrophage differentiation and polarization 
For differentiation towards macrophages freshly isolated monocytes were incubated in RPMI 1640 
(supplemented with 5% (v/v) FCS, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin 
(100 µg/mL)) and recombinant human macrophage colony stimulating factor (rhM-CSF) (25 
ng/mL) for 6 d as reported [233]. After 6 d incubation unpolarized macrophages were activated 
and polarized by supplementing the medium for further 24 h with either LPS (100 ng/mL) alone 
or in combination with recombinant human IFN-γ (100 ng/mL) for M1 polarized macrophages or 
with recombinant human IL-4 (20 ng/mL) for M2 polarized macrophages [150, 233]. 
3.2.1.3 MDA-MB-231 
MDA-MB-231 cells (human gland/breast epithelial cancer cell line) were cultured in Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% (v/v) heat-inactivated FCS, penicillin 
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(100 U/mL), and streptomycin (100 µg/mL) at 37 °C/5% CO2. Cells were detached by trypsin-
EDTA for 10 min at 37 °C/5% CO2 three times per week, resuspended in DMEM and seeded at a 
concentration of 0.15 × 106/mL at 37°C/5% CO2. 
 Determination of cell viability 
The viability of macrophages and MDA-MB-231 cells was assessed by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described [234]. Thus, cells were 
resuspended in the appropriate medium and seeded into 96 well plates (106/mL; 100 µL/well) for 
1 h at 37 °C/5% CO2. Cells were then preincubated with compounds or vehicle (0.3% DMSO) for 
30 min, MDA-MB-231 stimulated with LPS (100 ng/mL) and macrophages with LPS (100 ng/mL) 
with or without IFN-γ (100 ng/mL), with IL-4 (20 ng/mL), or left untreated for 24 h and 48 h, 
respectively, at 37 °C/5% CO2. MDA-MB-231 were additionally incubated with cell culture 
supernatants of macrophages which had been treated with archazolid at indicated concentrations 
or vehicle (DMSO) before (in detail described in 3.2.7). MTT (5 mg/mL) was added, cells were 
further incubated for four hours until blue formazan crystals due to reduction of MTT by viable 
cells were visible, and lysed in a sodium dodecyl sulfate (SDS)-lysis buffer (10% (w/v) SDS, HCl 
(20 mM); pH 4.5) with shaking at room temperature in the dark. After 20 h absorption was 
measured at 570 nm with a microplate reader (Thermo Fisher Scientific Inc., MA). 
Exclusion of trypan blue was used to control cell viability of macrophages after differentiation. 
Thus, the macrophage suspension was added to a trypan blue solution and cells counted by a Vi-
cell counter (Beckman Coulter GmbH, Krefeld, Germany). Successful plasma membrane 
destruction after sonification for cell homogenates was visualized by exclusion of trypan blue as 
well. 
 Analysis of vesicular pH 
The pH measurements were performed as reported [235] and sodium buffer (NaCl (135 mM), KCl 
(5 mM), CaCl2 (1 mM), MgSO4 (1 mM), KH2PO4 (2 mM), glucose (5 mM), HEPES (6 mM)) and 
potassium buffer ((NaCl (10 mM), KCl (130 mM), CaCl2 (1 mM), MgSO4 (1 mM), NaH2PO4 (2 
mM), glucose (5 mM), HEPES (6 mM)) were used as described [236]. For measurements of 
vesicular pH, monocytes (106/mL) were differentiated into macrophages. At day 6, macrophages 
were incubated with fluorescein isothiocyanate (FITC)-labelled dextran (0.5 mg/mL; 70,000 Da) 
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for 1 h at 37°/5% CO2. Cells were washed with D’PBS, preincubated with compounds or vehicle 
(0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h at 37 °C/5% CO2. The 
pH values were calculated from the ratio of fluorescence intensities at the excitation wavelengths 
of 480 nm and 450 nm and emission at 520 nm, measured with a NOVOstar microplate reader 
(BMG Labtech, Ortenberg, Germany). In situ fluorescence calibration was performed with the 
ionophore nigericin (10 µM) in potassium buffer at pH values between 4.5 and 7.5. 
Imaging of FITC-dextran uptake was performed with macrophages (0.25 × 106/mL) seeded onto 
glass bottom dishes and apart from that as described for analysis of vesicular pH. After washing, 
uptake of FITC-dextran into acidic organells was imaged using an Axio Observer.Z1 inverted 
microscope and a LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 objective (Carl Zeiss, Jena, 
Germany). 
For imaging of acidic organelles by LysoTracker staining, macrophages (0.25 × 106/mL) were 
resuspended in RPMI 1640 without phenol red and plated onto glass bottom dishes. After 
adherence, cells were treated with compounds or vehicle (0.1% DMSO) for 30 min and stimulated 
with LPS (100 ng/mL) for 24 h. Macrophages were then stained with a fluorescent LysoTracker 
dye (50 nM) for 1 h. After washing, red fluorescence of the protonated and accumulated probe in 
acidic cell organelles was imaged microscopically (Axio Observer.Z1, LCI Plan-Neofluar 63x/1.3 
Imm Corr DIC M27 objective; Carl Zeiss, Jena, Germany). 
 Investigation of phagocytic activity 
For determination of phagocytic activity, opsonized zymosan was prepared as reported [237]. 
Briefly, zymosan (20 mg/mL) was pre-treated by heating in a boiling water bath for 20 min, 
sonificated (SFX250, Branson, CT), washed and resuspended in Hank’s balanced salt solution 
(HBSS) buffer. Opsonization was obtained by incubation with human serum (65% (v/v)) at a 
concentration of 20 mg/mL for 60 min at 37 °C. For assessing phagocytosis in living cells, 
macrophages (0.25 × 106/mL) were resuspended in HBSS and plated onto glass bottom dishes. 
After adherence, cells were pre-treated with compounds or vehicle (0.1% DMSO) for 30 min and 
stimulated with LPS (100 ng/mL) for 24 h. Phagocytosis was started by adding the particle 
suspension (1 mg/mL) at 37 °C/5% CO2 and microscopic live cell imaging was started 
immediately (see 3.2.6). 
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 Immunofluorescence microscopy 
Macrophages (0.25 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, 
L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), seeded in 12 well 
plates containing glass coverslips and incubated for 1 h at 37 °C/5% CO2 to ensure cell attachment. 
For immunofluorescence analysis of v-ATPase, macrophages were pre-incubated with compounds 
or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL), LPS (100 ng/mL)/IFN-
γ (100 ng/mL) for M1, or with IL-4 (20 ng/mL) for M2 for 24 h at 37 °C/5% CO2. For microscopic 
analysis of IκB and NF-κB, macrophages were pre-incubated with compounds or vehicle for 16 h 
and stimulated with LPS (100 ng/mL) for 15 min at 37 °C/5% CO2. Cells were fixed with 
paraformaldehyde (PFA) solution (4% (w/v)) and autofluorescence of free formaldehyde was 
quenched with ammonium chloride (50 mM). For visualization of 5-LO translocation and FLAP 
co-localization, macrophages were pre-incubated with compounds or vehicle for 16 h and 
stimulated with Ca2+-ionophore A23187 (2.5 µM) for 3 min. Cells were fixed with ice-cold 
methanol (100%) for 20 min at -20 °C. Permeabilization was achieved by treatment with Triton 
X-100 (0.2% (v/v)). After blocking with non-immune goat serum (10% (v/v)), samples were 
incubated with antibodies over night at 4 °C as indicated (Table 3.1). The samples were extensively 
washed and then stained with the fluorophore-labeled secondary antibodies Alexa Fluor 488 goat 
anti-rabbit IgG (1:500) and Alexa Fluor 555 goat anti-mouse IgG (1:500) for 10 min at room 
temperature in the dark. DNA was stained using 4',6-diamidino-2-phenylindole (DAPI) (0.7 
µg/mL) for 3 min at room temperature. Samples were placed on microscope slides using Mowiol 
containing n-propyl gallate (0.25%). The slides were stored at 4 °C in the dark until microscopic 
analysis.  
Table 3.1: Primary antibodies for immunofluorescence. Antibodies were diluted with BSA (5% (w/v)) in sterile PBS 
antibody source dilution 
IκBα mouse, monoclonal 1:125 
NF-κB p65 rabbit, monoclonal 1:100 
5-LO mouse, monoclonal 1:100 
FLAP rabbit, polyclonal 1:150 
ATP6V0A2 rabbit, polyclonal 1:250 
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The fluorescence was visualized with an Axio Observer.Z1 inverted microscope and a LCI Plan-
Neofluar 63x/1.3 Imm Corr DIC M27 objective. Images were taken with an AxioCam MR3 
camera and acquisition was done with AxioVision 4.8 software (All components Carl Zeiss, Jena, 
Germany). 
 Live cell imaging 
For imaging of living cells, macrophages (0.25 × 106/mL) were resuspended in RPMI without 
phenol red and plated into glass bottom dishes. After treatments, macrophages were imaged at 37 
°C/5% CO2 using the incubator unit XLmulti S1 including the heater unit XL S1 and the CO2 
module S1 for the Axio Observer.Z1 inverted microscope and a Plan-Apochromat 40x/1,3 Oil DIC 
M27 objective or a LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 objective. If necessary, definite 
focus for Axio Observer.Z1 was used for focussing macrophages automatically over a pre-set 
timespan. Images were taken with an AxioCam MR3 camera and acquisition was done with 
AxioVision 4.8 software. 
 
 Determination of extracellular cytokine levels 
Monocytes (106/mL), resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-glutamine 
(2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), were plated into 24-well plates 
and incubated for 1-2 hours before rhM-CSF (25 ng/mL) was added, and cells further incubated 
for 6 d at 37 °C/5% CO2. At day 6, unpolarized macrophages were pre-incubated with compounds 
or vehicle for 30 min and polarized with LPS (100 ng/mL) alone or with INF-γ (100 ng/mL) for 
M1 or with IL-4 (20 ng/mL) for M2 at 37 °C/5% CO2. After 24 h, supernatants were collected, 
centrifuged (400 × g/10 min/4 °C) (Centrifuge 5424 R, Eppendorf, Hamburg, Germany), and 
stored at -20 °C. Cytokines (IL-1β, IL-6, IL-8, IL-10, TNFα, MCP-1) in supernatants were 
analyzed by in-house made ELISA. 
 Determination of extracellular PGE2 levels 
Supernatants of macrophages were obtained as described in 3.2.7. PGE2 was either analyzed by a 
commercially available ELISA kit (Biotrend Chemikalien GmbH, Köln, Germany) or by ultra 
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performance liquid chromatography (UPLC)-coupled ESI tandem mass spectrometry (MS/MS) as 
described in chapter 3.2.11. 
 Determination of eicosanoid release 
Monocytes (1.5 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, 
L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), plated into 12-well 
plates and incubated with rhM-CSF (25 ng/mL) for 6 days at 37 °C/5%CO2 to obtain differentiated 
macrophages. For long-term incubations (24 h), macrophages were pre-incubated with compounds 
or vehicle (0.1% DMSO) for 30 min and then stimulated with either LPS (100 ng/mL), LPS (100 
ng/mL)/IFN-γ (100 ng/mL) for M1, or IL-4 (20 ng/mL) for M2 for 24 h at 37 °C/5% CO2. Then, 
eicosanoid formation was stimulated by addition of Ca2+-ionophore A23187 (2.5 µM) for 10 min 
at 37 °C and cells were placed on ice to stop the reaction. For analysis of effects of compounds on 
short-term prostanoid formation (30 min), macrophages were stimulated with LPS (100 ng/mL) or 
LPS (100 ng/mL)/IFN-γ (100 ng/mL) for 24 h at 37 °C/5% CO2. Fresh RPMI 1640 (supplemented 
with 0.5% (v/v) FCS, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)) 
was added and cells incubated for 30 min at 37 °C/5% CO2 before they were pre-incubated with 
compounds or vehicle (0.1% DMSO) for 15 min at 37 °C and subsequently stimulated with Ca2+-
ionophore A23187 (2.5 µM) plus AA (5 µM) for 30 min at 37 °C to induce product formation. 
Incubations were terminated by placing the cells on ice. HCl (30 µL/mL; 1 M) for protonation of 
lipid mediators and PGB1 (60 ng) as internal standard was added before samples were extracted 
by solid phase extraction (SPE) (3.2.10). 
 Solid phase extraction 
For the preparation of the samples for eicosanoid analysis, the samples were centrifuged (400 × 
g/10 min/4 °C) and transferred to C18 SPE columns, which were conditioned before with 1 mL 
methanol (100%) and 1 mL water. Samples were washed twice with 0.5 mL water and eluted with 
300 µL methanol (100%). After centrifugation (15,000 × g/5 min/ 4 °C) eicosanoids were analyzed 
by UPLC-MS/MS analysis as described in chapter 3.2.11. 
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 UPLC-MS/MS analysis 
UPLC-MS/MS analysis was performed with an Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 
50 mm, Waters, Milford, MA) using an AcquityTM UPLC system (Waters, Milford, MA). 
Chromatography was performed at a flow rate of 0.8 mL/min and a column temperature of 45 °C. 
The solvents for the mobile phase were water/acetonitrile (90/10; A) and acetonitrile (B) both 
acidified with 0.07% (v/v) formic acid. Isocratic elution at A/B = 70/30 was performed for 2 min 
and followed by a linear gradient to A/B = 30/70 within 5 min. The chromatography system was 
coupled to a QTRAP 5500 mass spectrometer (AB Sciex, Darmstadt, Germany) equipped with a 
Turbo VTM source and electrospray ionization (ESI) probe. Eicosanoid identification is based on 
the detection of specific fragment ions (listed in Table 3.2) through multiple reaction monitoring 
(MRM) using the negative ion mode in combination with retention times. 
Table 3.2: metabolite fragment ions and conditions used in MRM. Q1, first quadrupole; Q3, third quadrupole; CE, 
collision energy 
 transition I transition II  
metabolite Q1 [m/z] 
Q3 
[m/z] 
CE 
[eV] 
Q1 
[m/z] 
Q3 
[m/z] 
CE 
[eV] 
retention time 
[min] 
PGB1 335 113 -31 335 221 -28 1,69 
PGE2 351 189 -22 351 271 -20 0,62 
TxB2 369 195 -18 369 169 -25 0,45 
12-HHT 279 163 -30 - - - 3,30 
11-HETE 319 167 -21 - - - 4,70 
PGF2α 353 193 -35 - - - 0,56 
LTB4 335 129 -26 335 195 -22 2,68 
Epi/trans LTB4 335 195 -22 - - - 2,58 
5-HETE 319 115 -20 319 203 -20 5,04 
12-HETE 319 179 -18 - - - 4,81 
15-HETE 319 219 -18 - - - 4,54 
5-HETrE 321 115 -19 - - - 5,71 
5-HEPE 317 115 -17 - - - 4,37 
 
Parameters were set as follows: The ion spray voltage was -4500 V, the heater temperature 500 
°C, the declustering potential -30 to -120 eV, the entrance potential -5 to -10 eV, the cell exit 
potential -11 to -17 eV, the curtain gas pressure 35 psi, the nebulizer gas pressure 50 psi, the Turbo 
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V gas pressure 80 psi. Analyst 1.6 software (AB Sciex, Darmstadt, Germany) was used for 
automatic peak integration using IntelliQuan default settings. Data were normalized on the internal 
standard PGB1, and are given as relative intensities. 
 Determination of kinase activation, STAT1/3- and IκB 
phosphorylation, and NF-κB activity 
Monocytes (2 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), and incubated with 
rhM-CSF (25 ng/mL) for 6 d at 37 °C/5% CO2. After differentiation, macrophages were first 
starved for 6 h (AKT, ERK, p38, MEK1/2, SAPK/JNK, MEK3/6) or directly pre-incubated 
(NFκB, IκB, STAT1, STAT3) with compounds or vehicle (0.1% DMSO) for 16 h at 37 °C/5% 
CO2. 5% (v/v) FCS was added to starved cells prior to stimulation with LPS (100 ng/mL) for 15 
min. After stimulation, macrophages were immediately placed on ice, washed once with D’PBS 
and lysed as described in 3.2.15. Lysates were finally used for protein separation by SDS-PAGE 
and subsequent Western blot analysis as described in 3.2.16. 
 Determination of v-ATPase, COX-2, and 5-LO expression 
Monocytes (2 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), and differentiated with 
rhM-CSF (25 ng/mL) for 6 d at 37 °C/5% CO2. Macrophages were pre-incubated with compounds 
or vehicle (0.1% DMSO) for 30 min and activated with LPS (100ng/mL), LPS (100 ng/mL) plus 
INF-γ (100 ng/mL) or IL-4 (20 ng/mL) for 24 h at 37 °C/5% CO2. Then, cells were immediately 
placed on ice, washed once with D’PBS and lysed as described in 3.2.15 before they were used 
for protein separation by SDS-PAGE and subsequent Western blot analysis (3.2.16). 
 Subcellular fractionation 
Monocytes (2 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)), and differentiated with 
rhM-CSF (25 ng/mL) for 6 d at 37 °C/5% CO2. Macrophages were pre-treated with compounds 
for 30 min at 37 °C/5% CO2 and stimulated with LPS (100 ng/mL) for 24 h. Cells were detached 
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with biotase, collected by centrifugation (400 × g/10 min/4 °C), and lysed with 200 µL TKM 
buffer (Tris (50 mM), sucrose (250 mM), KCl (25 mM), MgCl2 (5 mM), EDTA (1 mM), and 
freshly added leupeptin hemisulfate salt (10 µg/mL), trypsin inhibitor from soybean (STI) (60 
µg/mL), phenylmethylsulfonyl fluoride (PMSF) (1 mM)) with subsequent sonification (output 3, 
cycle 10%, 10 cycles) (SFX250, Branson, CT) on ice. Cell disruption was checked microscopically 
by trypan blue exclusion. Except for 20 µL which were saved for Western blot analysis, the total 
lysate was centrifuged at 13,000 × g/15 min/4 °C. The supernatant contained the cytoplasmic 
fraction (S13), the pellet was lysed in 200 µL TKM buffer yielding the P13 fraction, representing 
the nucleus, rough ER, DNA. The P13 lysate was transferred into ultracentrifuge tubes and 
centrifuged at 100,000 × g/1.5 h/ 4 °C (LE-80 ultrazentrifuge, Beckman Coulter, Krefeld, 
Germany). The pellet was again lysed in 200 µl TKM buffer and sonificated until solubilization. 
10 µL of each fraction was retained for determination of protein concentration by a protein assay 
(Bio-Rad Laboratories, CA). To each fraction 4 × loading buffer (Tris/HCl (40 mM) pH 8, EDTA 
(4 mM), 10% (w/v) SDS, 10% (v/v) β-mercaptoethanol) and bromphenol blue (0.05% (w/v) in 
50% (v/v) glycerol) was added and the samples boiled for 5 min at 96 °C. The samples were 
collected by centrifugation and stored at -20 °C before protein separation by SDS-PAGE and 
Western blotting for v-ATPase (3.2.16). 
 Generation of whole cell lysates for Western blot 
Macrophages were lysed with a NP-40 lysis buffer (1% (v/v) NP-40, sodium vanadate (1 mM), 
sodium fluoride (10 mM), sodium pyroshosphate (5 mM), β-glycerosphosphate (25 mM), EDTA 
(5 mM), and freshly added leupeptin hemisulfate salt (10 µg/mL), STI (60 µg/mL), PMSF (1 mM) 
in Tris-buffered saline (TBS: Tris/HCl (50 mM), NaCl (100 mM)); pH 7.4) for 30 min on ice with 
occasional vortexing. Lysates were centrifuged (10,000 × g/4 °C/5 min) and protein concentration 
in the supernatants were determined using a Protein Assay (Bio-Rad Laboratories, CA). After 
addition of 4 × SDS loading buffer (Tris/HCl (50 mM; pH 6.8), SDS (2% (w/v)), glycerol (10% 
(v/v)), β-mercaptoethanol (1% (v/v)), EDTA (12.5 mM), bromphenol blue (0.02% (w/v))), 
samples were boiled for 5 min at 96 °C, lysates collected by centrifugation and stored at -20 °C 
before protein separation by SDS-PAGE (3.2.16). 
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 SDS-PAGE and Western blot 
Proteins from cell lysates were separated by vertical SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) using a Mini-Protean electrophoresis system (Mini-PROTEAN® Tetra Cell, Bio-
Rad Laboratories Inc., Hercules, CA) and a running buffer (glycine (192 mM), Tris (25 mM), SDS 
(3.5 mM)). The applied pre-stained marker peqGOLD allowed to analyze proteins in the range of 
10 to 170 kDa. Proteins were transferred from polyacrylamide gels on nitrocellulose membranes 
(Amersham Biosciences, Little Chalfont, UK) with a tank blotting method (Mini Trans-Blot® cell 
and PowerPac™ Basic power supply, Bio-Rad Laboratories Inc., Hercules, CA) in transfer buffer 
(glycine (39 mM), Tris (48 mM), 20% (v/v) methanol) at 90 V for 90 min. Protein transfer was 
controlled by Ponceau staining (5% (w/v) Ponceau S in 5% (v/v) acetic acid). Membranes were 
washed, blocked with 5% (w/v) BSA or 5% (w/v) low fat powdered milk in TBS-Tween (TBS, 
0.1% (v/v) Tween®20) for 1 h at room temperature and incubated with primary antibodies (Table 
3.3) overnight at 4 °C. Membranes were washed twice in TBS-Tween and incubated with 
fluorescently-labeled secondary antibodies IRDye 800CW (dilution 1:10,000) and IRDye 680LT 
(dilution 1:80,000) for 1 h at room temperature in the dark. Membranes were washed again twice 
in TBS-Tween and further twice in TBS before drying for 30 min at 37 °C in the dark. Proteins 
were detected using the Odyssey Infrared Imaging System (LI-COR Biosciences, Bad Homburg, 
Germany) and analyzed with the Odyssey application software. 
Table 3.3: Primary antibodies used for Western blot analysis. Antibodies were diluted in 5% BSA/TBS-Tween or 5% 
low fat powdered milk in TBS-Tween. 
antibody (and phosphorylation site) source dilution 
IκBα mouse, monoclonal 1:1000 
phospho-IκBα (Ser32) rabbit, monoclonal 1:500 
NF-κB p65 rabbit, monoclonal 1:500 
phospho-NF-κB p65 (Ser536) mouse, monoclonal 1:500 
phospho-STAT1 (Tyr701) rabbit, polyclonal 1:1000 
phospho-STAT3 (Tyr705) rabbit, monoclonal 1:1000 
MEK1/2 rabbit, polyclonal 1:1000 
phospho-MEK1/2 (Ser217/221) rabbit, polyclonal 1:1000 
p44/42 (ERK1/2) rabbit, polyclonal 1:1000 
phospho-p44/42 (ERK1/2) (Thr202/Tyr204) mouse, monoclonal 1:1000 
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Table 3.3 (continued): Primary antibodies used for Western blot analysis. 
antibody (and phosphorylation site) source dilution 
phospho-MEK3/6 (Ser189) (Ser207) rabbit, monoclonal 1:1000 
p38 rabbit, monoclonal 1:1000 
phospho-p38 (Thr180/Tyr182) rabbit, polyclonal 1:1000 
phospho-SAPK/JNK (Thr183/Tyr185) mouse, monoclonal 1:1000 
AKT mouse, monoclonal 1:1000 
phospho-AKT (Ser473) rabbit, polyclonal 1:1000 
GAPDH mouse, monoclonal 1:1000 
β-actin mouse, monoclonal 1:1000 
 
 Generation of cell homogenates 
To generate cell homogenates, macrophages (106/mL) were resuspended in RPMI 1640 
(supplemented with 5% (v/v) FCS, L-glutamine (2 mM), penicillin (100 U/mL), and streptomycin 
(100 µg/mL)), pre-incubated with compounds for 30 min and polarized with LPS (100 ng/mL) 
plus INF-γ (100 ng/mL) for M1 or with IL-4 (20 ng/mL) for M2 for 24 h at 37 °C/5%CO2. 
Macrophages were detached with biotase and collected by centrifugation (400 × g/10 min/4 °C). 
Cells were then washed with D’PBS-EDTA (1 mM) and sonicated on ice (output 1, cycle 40%, 12 
cycles) (SFX250, Branson, CT). Cell disruption was proved by trypan blue exclusion and 
microscopic analysis. Sonification was repeated if necessary. Lysates were distributed according 
to 3.5 × 106 cells/sample and product formation stimulated with CaCl2 (2 mM) and AA (20 µM) 
for 15 min at 37 °C. Finally, the reaction was stopped by placing the cells on ice, HCl (30 µL/mL;1 
M) and PGB1 (60 ng) were added, the samples were centrifuged (2000 × g/10 min/4 °C) and used 
for SPE (3.2.10) before analysis by UPLC-MS/MS (3.2.11). 
 Analysis of mRNA expression and degradation 
Monocytes (2 × 106/mL) were resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL)). After 6 d of 
differentiation with rhM-CSF (25 ng/mL), macrophages were pre-incubated with compounds or 
vehicle (0.1% DMSO) for 30 min or 16 h, respectively, and stimulated with LPS (100 ng/mL) for 
indicated times at 37 °C/5% CO2. For measurement of TNFα mRNA degradation, macrophages 
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were stimulated with LPS (100 ng/mL) for 24 h and incubated with compound or vehicle (0.1% 
DMSO) for 1 h. Then, transcription was stopped by addition of actinomycin (5 µg/mL) and cells 
were incubated for the indicated times. Total RNA from macrophages was isolated using the 
E.Z.N.A.® Total RNA Kit I (Omega Biotek, GA, ). Total mRNA amount was determined by 
photometric analysis at 230 nm, 260 nm, 280 nm, and 320 nm measured by Nanodrop (Thermo 
Fisher Scientific Inc., MA) and calculation of the ratios A260 nm/A280 nm and A260 nm/A230 
nm confirmed the quality of the mRNA. cDNA was generated by reverse transcription by 
SuperScript® III First-Strand Synthesis SuperMix (Life technologies, CA) with random hexamers 
and a thermal cycling protocol as follows: 5-10 min at 25 °C, 50 min at 50 °C, 5 min at 85 °C. The 
cDNA was amplified by PCR (Mx3005P qPCR system, Agilent Technologies, CA) using the 
primers listed in Table 3.4 and according to the PCR conditions described in Table 3.5.  
Table 3.4: Primers for qRT-PCR. Primers were diluted in nuclease-free water to 0.3 µM 
name strand nucleotide sequence 
beta-2-microglobulin (B2M) 
forward 5´- CTCCGTGGCCTTAGCTGTG -3´ 
reverse 5´- TTTGGAGTACGCTGGATAGCCT -3´ 
TNFα 
forward 5’- CCCAGGGACCTCTCTCTAATC -3’ 
reverse 5’- ATGGGCTACAGGCTTGTCACT -3’ 
IL-1β 
forward 5’- ACAGATGAAGTGCTCCTTCCA -3’ 
reverse 5’- GTCGGAGATTCGTAGCTGGAT -3’ 
COX-2 
forward 5’- TGCATTCTTTGCCCAGCACT -3’ 
reverse 5’- AAAGGCGCAGTTTACGCTGTC -3’ 
 
Table 3.5: Three-step cycling protocol for thermal cycler.  
step temperature time number of cycles 
initial 
denaturation 95 °C 10 min 1 
denaturation 95 °C 15 sec 
45 annealing 60 °C 30 sec 
extension 72 °C 30 sec 
termination 
95 °C 60 sec 
1 55 °C 30 sec 
95 °C 30 sec 
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For quantification Maxima SYBR Green/ROX qPCR Master Mix (Fermentas, Darmstadt, 
Germany) was used. To calculate the relative TNFα mRNA expression (normalized to B2M) the 
2(-ΔΔC(T)) method was used [238]. Data acquisition was done by the MxPro software 
(Mx3005P®/version 4.10, Agilent Technologies, CA). 
 Determination of [3H]-AA release 
Tritium-labeled AA was used to determine cPLA2 activity by measuring AA release from 
macrophages. Thus, macrophages (0.5 × 106/mL) were incubated with 2.5 nM [3H]-AA 
(corresponding to 0.25 μCi/mL; specific activity 100 Ci/mmol) in RPMI 1640 without additives 
for 24 h at 37 °C/5% CO2. Cells were collected by centrifugation (400 × g/10 min/4 °C) and 
washed twice with PG buffer (D’PBS plus 0.1% (w/v) glucose) containing fatty acid-free bovine 
serum albumin (BSA) (2 mg/mL) to remove unincorporated [3H]AA. Macrophages were 
resuspended in buffer containing CaCl2 (1 mM) and distributed to 0.5 mL each in Eppendorf cups 
at a concentration of 2 × 106/mL. The samples were pre-incubated with compounds or vehicle 
(0.1% DMSO) for 10 min, then thiomersal (50 µM) was added to avoid re-acylation of 
unconverted AA into membranes and after 5 min, cells were stimulated with Ca2+-ionophore 
A23187 (2.5 µM) for 30 min at 37 °C. The reaction was stopped on ice for 10 min and cells were 
centrifuged (500 × g/15 min/20 °C). 300 µL of the supernatant was combined with 2 mL liquid 
scintillation counting (LSC) fluid and assayed for radioactivity by scintillation counting (Micro 
Beta Trilux, Perkin Elmer, MA). 
 Determination of reactive oxygen species (ROS) 
The measurement of ROS levels was performed as reported [239]. Briefly, monocytes (0.5 × 
106/mL), resuspended in RPMI 1640 (supplemented with 5% (v/v) FCS, L-glutamine (2 mM), 
penicillin (100 U/mL), and streptomycin (100 µg/mL)), were incubated with rhM-CSF (25 ng/mL) 
for 6 d. Macrophages were incubated with compounds or vehicle (0.1% DMSO) for 30 min and 
stimulated with LPS (100 ng/mL) for 24 h or left untreated. Cells were washed and incubated in 
HBSS buffer containing 2’-7’-dichlorofluorescein diacetate (DCFH-DA) (10 µM) for 30 min at 
37 °C/5% CO2. To detect and quantify intracellular formation of H2O2, fluorescence of the 
deacetylated dye (2’-7’-dichlorofluorescein) was measured at an excitation wavelength of 485 nm 
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and an emission wavelength of 535 nm using a NOVOstar microplate reader (BMG 
Labtechnologies GmbH, Offenburg, Germany). 
 Statistics 
The data are presented as mean + standard error of the mean (SEM) of n experiments, where n 
represents the number of experiments. Statistical data was analyzed using the GraphPad InStat 
software (GraphPad Software, CA), and was performed by Student’s t test for paired groups and 
by one-way ANOVA for independent or correlated samples followed by a Bonferroni (< 5 groups) 
or Tukey-Kramer (> 5 groups) post hoc test for multiple comparisons [240]. A P value of < 0.05 
(*) was considered significant. 
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4 RESULTS 
4.1 Influence of archazolid on macrophage function 
 v-ATPase expression and functionality 
For the investigation of the v-ATPase inhibitor archazolid and its effects on macrophages, the 
expression and localization of the v-ATPase in LPS-stimulated (M), LPS/INF-γ (M1), and IL-4 
(M2) polarized macrophages was examined by immunofluorescence microscopy and Western blot 
analysis (Figure 4.1; A and B). 
In agreement with other studies [241-243] the expression of the v-ATPase could be confirmed for 
macrophages and was further shown to be independent of the stimulation with LPS, LPS/INF-γ, 
or IL-4, since immunolabeling and microscopic analysis did not reveal visible differences of the 
enzyme’s localization between the macrophage subtypes. Western blot analysis confirmed that the 
A B 
Figure 4.1: Expression and localization of the v-ATPase in macrophages. (A) Macrophages were pre-treated with 
archazolid (Arc B) at indicated concentrations or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 
ng/mL)/IFN-y (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. Cells were fixed, permeabilized, and incubated with an 
antibody against v-ATPase (green), followed by Alexa Fluor 488 goat anti-rabbit IgG. Nuclei were stained with DAPI 
(blue). Results are representative of three independent experiments. (B) Macrophages were pre-treated and stimulated 
as described in Fig. 4.1 (A). Cells were lysed with TKM buffer followed by sonification and fractions were obtained 
by centrifugation at 13,000 × g (S13, P13) and 100,000 × g (P100). Samples were analyzed by Western blotting. β-
Actin was used as control. Representative Western blots of two independent experiments are shown. 
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v-ATPase is primarily expressed in the P13 fraction which represents mainly membranes of ER 
and nucleus, whereas P100 contains partly microsomal membranes and plasma membranes where 
the v-ATPase was found, too, but in a lower amount. Archazolid did not have an effect on 
expression or localization of the v-ATPase in any of the macrophage subtypes. Next, the 
functionality of the v-ATPase in macrophages, namely their main role to acidify lysosomal 
compartments, was ensured. Consistent with other inhibitors of the v-ATPase which have been 
shown to elevate the lysosomal pH in various cell types [210, 244], archazolid caused significantly 
increased vesicular pH in LPS-activated macrophages as evidenced by the pH-dependent 
internalization of FITC-labeled dextran (Figure 4.2, A). The successful uptake of FITC-dextran 
was confirmed by microscopic analysis (Figure 4.2, B). The pH elevation by archazolid occurred 
at least at 100 nM but only slightly at 10 nM. Chloroquine (CQ; 100 µM) and NH4Cl (50 mM) 
also moderately elevated lysosomal pH (Figure 4.2, A) in agreement with the literature [235, 245-
247]. These findings were also supported by the results obtained by staining of acidic organelles 
A B 
C 
Figure 4.2: Effects of v-ATPase inhibition on lysosomal pH of human macrophages. (A, B) Macrophages were
incubated with FITC-Dextran (0.5 mg/mL) for 60 min, pre-incubated with archazolid (Arc B) at indicated 
concentrations, NH4Cl (50 mM), chloroquine (CQ; 100 µM), or vehicle (0.1% DMSO) for 30 min and stimulated with 
LPS (100 ng/mL) for 24 h. FITC-Dextran uptake into lysosomes was determined by measurement of emission at 
520 nm (A) or by analysis of immunofluorescence pictures (FITC-dextran: green; differential interference contrast)
(B). (C) Macrophages were pre-incubated with archazolid (Arc B; 100 nM), apicularen (Apic A; 100 nM), NH4Cl
(50 mM) or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h, followed by incubation 
with LysoTracker (50 nM; red) for 60 min. Values shown are percentages of vehicle control, means + SEM; n=8 (A). 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS-stimulated vehicle (DMSO). ANOVA + Bonferroni post-hoc test. 
Pictures shown are representative of three independent experiments. 
Results 
 
46 
with the pH sensitive LysoTracker probe and fluorescence microscopy (Figure 4.2, C). Here, the 
structurally different v-ATPase inhibitor apicularen also caused the alkalization of acidic 
organelles as well as the alkalizing control NH4Cl. 
 Viability of M, M1, and M2 
Since v-ATPase inhibitors have been in the focus of investigation particularly concerning their 
ability to induce apoptosis causing cancer cell death [5], the effect of archazolid on macrophage 
viability was examined by MTT assay. Pre-treatment of LPS, LPS/INF-γ, or IL-4 activated 
macrophages with archazolid (1 – 10 – 100 nM) for 24 h and 48 h, respectively, revealed no loss 
of cell viability, whereas the protein kinase inhibitor and apoptosis inducer staurosporine (3 µM) 
completely abolished cell viability (Figure 4.3). 
A 
B 
Figure 4.3: Viability of macrophages. Macrophages were pre-incubated with archazolid (Arc B) at indicated 
concentrations, staurosporine (stauro; 3 µM) or vehicle (0.3% DMSO) for 30 min and stimulated with LPS 
(100 ng/mL), with LPS (100 ng/mL)/IFN γ (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h (A) and 48 h (B). Cell viability 
was determined by MTT assay. Values shown are percentages of vehicle control, means + SEM; n = 3. 
***P < 0.001 vs. the LPS, LPS/IFN-γ or the IL-4-treated vehicle (DMSO). ANOVA + Bonferroni post-hoc test. 
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 Morphology of M, M1, and M2  
Microscopic analysis additionally confirmed cellular integrity of macrophages upon archazolid 
treatment for 24 h and revealed significant alterations of the cell shape for LPS- and LPS/IFN-γ-
treated cells which was not evident for M2 for which the morphology was obviously not affected. 
 
 Phagocytosis 
Since macrophages are typical members of the phagocyte system, we examined if archazolid 
affects this cell specific functionality. Successful engulfment of serum-opsonized zymosan 
particles after archazolid treatment revealed that phagocytosis of LPS-stimulated macrophages is 
Figure 4.4: Morphological changes of 
stimulated macrophages by archazolid. 
Macrophages were pre-incubated with 
archazolid (Arc B; 100 nM) or vehicle (0.1% 
DMSO) for 30 min and stimulated with LPS 
(100 ng/mL), LPS (100 ng/mL)/IFN-γ 
(100 ng/mL), or IL-4 (20 ng/mL) for 24 h. Images 
are shown as differential interference contrast. 
Results are representative of three independent 
experiments. 
Figure 4.5: Phagocytosis of serum-opsonized 
zymosan by LPS-stimulated macrophages. 
Macrophages were pre-treated with archazolid 
(Arc B; 100 nM), cytochalasin (Cyto B; 10 µM) or 
vehicle (0.1% DMSO) for 30 min and stimulated 
with LPS (100 ng/mL) for 24 h. Phagocytosis was 
initiated by addition of serum-opsonized zymosan 
suspension (1 mg/mL) (0 min), pictures were taken 
every 30 sec. Images are shown as differential 
interference contrast. Results are representative 
of two independent experiments. Red arrows 
indicate ingested zymosan particles at indicated 
time points. 
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not impaired in comparison to cytochalasin B which was used as reference control since this 
compound is known to suppress phagocytosis [248]. 
4.2 Effects of archazolid on macrophages 
 Cytokine release 
After excluding that archazolid exhibits cytotoxicity against macrophages or detrimental impact 
on cellular integrity, viability, or phagocytic activity, the v-ATPase inhibitor was analyzed in view 
of its possible modulation of cytokine release from macrophages since these mediators play an 
important role in inflammatory events and inflammation-triggered cancer. After differentiation of 
freshly isolated monocytes for 6 d with rhM-CSF (25 ng/mL), macrophages were pre-treated with 
compounds for 30 min and then either activated by LPS, or polarized using LPS/INF-γ towards 
M1 or using IL-4 towards M2 within 24 h. Analysis of MCP-1, IL-1β, IL-6, IL-8 and IL-10 in the 
medium revealed no significant modulation of the release of these proteins by archazolid, neither 
in M1 nor M2 polarized macrophages (Figure 4.6). However, the levels of TNFα were significantly 
Figure 4.6: Effects of v-ATPase inhibition on cytokine release from M1 and M2 polarized macrophages. 
Macrophages were preincubated with archazolid B (100 nM) for 30 min and stimulated with LPS (100 ng/mL)/
IFN-γ (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. Levels of cytokines in supernatants were analyzed by ELISA. 
Values shown are percentages of vehicle control, means + SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the 
LPS/IFN-γ stimulated vehicle (DMSO) or the IL-4-stimulated vehicle (DMSO), respectively. Paired t-test. Absolute 
values of LPS/IFN-γ stimulated 100% controls: MCP-1: 98 ± 43 ng/mL, IL-1β: 1710 ± 1465 pg/mL, IL-6: 31 ± 
9 ng/mL, IL-8: 52 ± 5 ng/mL, IL-10: 1212 ± 256 pg/mL, TNFα: 1992 ± 653 pg/mL. Absolute values of IL-4-stimulated
100% controls: MCP-1: 86 ± 35 ng/mL, IL-1β: 601 ± 403 pg/mL, IL-6: 11 ± 2 ng/mL, IL-8: 45 ± 5 ng/mL, IL-10: 819 
± 240 pg/mL, TNFα: 259 ± 87 pg/mL. n=3-7. 
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upregulated by 100 nM archazolid about 2.5-fold in M1, whereas the compound completely failed 
to alter TNFα levels in M2 (Figure 4.6). 
More detailed concentration response experiments for TNFα release showed that for macrophages 
activated with LPS or LPS/INF-γ the maximal effect was obtained at 30 nM archazolid 
(upregulation LPS: 338% ± 48%; LPS/INF-γ: 277% ± 22%) and slightly declined at 100 nM 
(upregulation LPS: 219% ± 39%; LPS/INF-γ: 243% ± 59%) (Figure 4.7, A). It should be noted 
Figure 4.7: Effects of v-ATPase inhibition on TNFα release. Macrophages were pre-incubated with archazolid
(Arc B), apicularen (Apic A), bafilomycin (Baf A1) at indicated concentrations, with dexamethasone (Dex; 1 µM) or 
with vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) or with LPS (100 ng/mL)/
IFN-γ (100 ng/mL) for 24 h. Levels of cytokines in supernatants were analyzed by ELISA. Values shown are 
percentages of vehicle control, means + SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS-stimulated vehicle 
(DMSO) or the LPS/IFN-γ stimulated vehicle (DMSO), respectively. ANOVA + Tukey post-hoc test. Absolute value of 
LPS-stimulated 100% control: 1383 ± 229 pg/mL (n = 6), absolute value of LPS/IFN-γ stimulated 100% control: 1906
± 273 pg/mL (A, n = 3) and 2347 ± 632 pg/mL (B, n = 6). 
A 
B 
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that in unstimulated macrophages (no LPS, INF-γ, or IL-4) archazolid was not effective in this 
manner. In contrast to archazolid, dexamethasone repressed TNFα levels both in LPS- (30% ± 7%) 
and LPS/IFN-γ-stimulated macrophages (24% ± 4%) (Figure 4.7, A).  
In order to investigate if the effect of archazolid is related to suppression of v-ATPase activity, the 
v-ATPase inhibitors bafilomycin A1 and apicularen A were tested in the same experimental 
settings. For both compounds, upregulation of TNFα levels was evident with maximal effects at 
10 nM (Figure 4.7, B). 
 pH elevation and TNFα release 
As shown in 4.1.1/Figure 4.2, v-ATPase inhibition as well as the control substances chloroquine 
and NH4Cl led to elevated pH in lysosomal compartments. Furthermore, all tested v-ATPase 
inhibitors increased TNFα levels in LPS- and LPS/INF-γ-stimulated macrophages (Figure 4.7). 
Thus, chloroquine and NH4Cl were investigated for their effects on TNFα release from 
macrophages to see if pH elevation may elevate TNFα levels. In contrast to archazolid, chloroquine 
(100 µM) and NH4Cl (50 mM) markedly repressed TNFα release from LPS-activated and 
LPS/INF-γ polarized macrophages (Figure 4.8) suggesting that other mechanism than solely 
elevation of lysosomal pH due to inhibition of v-ATPase is responsible for the TNFα-upregulatory 
effects of archazolid. 
Figure 4.8: Effect of pH-elevating agents on TNFα 
release from macrophages. Macrophages were pre-
incubated with archazolid (Arc B; 10 nM), NH4Cl 
(50 mM), chloroquine (CQ; 100 µM) or vehicle 
(0.1% DMSO) for 30 min and stimulated with LPS 
(100 ng/mL) or LPS (100 ng/mL)/IFN-γ (100 ng/mL) for 
24 h. TNFα levels in supernatants were analyzed by 
ELISA. Values shown are percentages of vehicle control, 
means + SEM; n=3. *P < 0.05, **P < 0.01, ***P < 
0.001 vs. the LPS-stimulated vehicle (DMSO) or the 
LPS/IFN-γ stimulated vehicle (DMSO), respectively. 
ANOVA + Bonferroni post-hoc test. 
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 TNFα mRNA expression and degradation 
The stimulatory effect of archazolid on TNFα release from LPS-activated macrophages was 
abrogated by co-incubation with dexamethasone (Figure 4.9, A). This led to the assumption that 
archazolid may affect the expression of TNFα at the transcriptional level. To determine mRNA 
levels, macrophages were pre-treated with or without 100 nM archazolid in the presence or absence 
of 1 µM dexamethasone 30 min or 16 h prior to stimulation with LPS. TNFα mRNA levels after 
4 h and after 8 h were significantly higher in the presence of archazolid versus cells treated with 
LPS alone, and also after 1 h and after 16 h, 20 h and 24 h, archazolid led to elevated amounts of 
TNFα mRNA (Figure 4.9, B). Note that dexamethasone effectively repressed the stimulatory 
effects of archazolid. mRNA of IL-1β which was used as control due to the lack of archazolid 
affecting IL-1β protein levels, was not increased by archazolid (Figure 4.9, B). Experiments using 
A B C 
Figure 4.9: Effects of archazolid on TNFα mRNA and degradation. (A) Macrophages were pre-incubated with 
archazolid (Arc B; 100 nM), with or without dexamethasone (Dex; 1 µM), or with vehicle (0.1% DMSO) for 16 h and 
stimulated with LPS (100 ng/mL) for 8 h. Levels of TNFα in supernatants were analyzed by ELISA. Values shown are 
percentages of vehicle control, means + SEM; n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS-stimulated
vehicle (DMSO). ANOVA + Bonferroni post-hoc test. (B) Macrophages were pre-incubated with archazolid 
(Arc B; 100 nM) for 30 min or with archazolid (Arc B; 100 nM) plus dexamethasone (Dex; 1 µM) for 16 h or with 
vehicle (0.1% DMSO) and stimulated with LPS (100 ng/mL) for indicated times. mRNA was extracted and determined 
by RT-qPCR. mRNA levels were normalized against B2M. Values shown are fold of control, means + SEM; n = 3-5. 
**P < 0.01, ***P < 0.001 vs. the unstimulated archazolid B treated sample. ANOVA + Tukey post-hoc test. (C) 
Macrophages were stimulated with LPS (100 ng/mL) for 24 h and incubated with archazolid (Arc B; 10 nM) or vehicle 
(0.1% DMSO) for 60 min. Transcription was stopped by addition of actinomycin D (5 µg/mL) and macrophages 
incubated for indicated times. RNA was extracted and determined by RT-qPCR. Values shown are percentages of 
control, means + SEM; n=3-4. 
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actinomycin D that blocks mRNA transcription [249] indicated that archazolid did not prevent 
TNFα mRNA degradation (Fig. 4C). 
 Transcription factors 
Having revealed that archazolid affects TNFα at the mRNA level and that dexamethasone 
abrogates these effects, the transcription factors NF-κB and IκB became interesting to investigate 
whether they are involved in elevating TNFα levels of macrophages. As analyzed by Western 
blotting, archazolid (10 and 100 nM) elevated the activation and phosphorylation of the p65 
subunit of NF-κB in LPS-activated macrophages (Figure 4.10, A), whereas it did not alter IκB 
phosphorylation (Figure 4.10, B). 
This NF-κB-stimulatory effect of archazolid could be confirmed by analysis of the translocation 
of activated NF-κB from the cytosol into the nucleus in LPS-stimulated macrophages by 
immunofluorescence microscopy. 10 nM archazolid increased the amount of the p65 subunit of 
NF-κB in the nucleus (stained with DAPI) of LPS-stimulated cells (Figure 4.11, lower series) 
whereas IκB was detectable in unstimulated but not verifiable in LPS-stimulated macrophages 
(Figure 4.11, upper series) probably due to its degradation upon LPS treatment. 
 
A B 
Figure 4.10: Effects of archazolid on NF-κB (A) and IkB (B). Macrophages were pre-incubated with archazolid 
(Arc B) at the indicated concentrations, with parthenolide (10 µM) with or without archazolid B or with vehicle 
(0.1% DMSO) for 16 h and stimulated with LPS (100 ng/mL) for 15 min or left unstimulated. Protein phosphorylation 
or expression in cell lysates were analyzed by Western blotting. Representative Western blots of three to six
independent experiments are shown. β-Actin or the appropriate unphosphorylated protein were used as control. 
Values shown are percentages of vehicle control, means + SEM; n = 4 (A, left panel); n = 3 (A, right panel); 
n = 3-6 (B). *P < 0.05, **P < 0.01, vs. the LPS-stimulated vehicle (DMSO). ANOVA + Bonferroni post-hoc test. 
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Further transcription factors like STAT1 and STAT3 were observed as differently activated by 
archazolid regarding stimulation of macrophages with LPS/IFN-γ or IL-4. Whereas archazolid at 
Figure 4.11: Macrophages were pre-incubated with 
archazolid (Arc B; 10 nM), or vehicle (0.1% DMSO) for 16 h 
and stimulated with LPS (100 ng/mL) for 15 min or left 
unstimulated. Fixed and permeabilized cells were stained with 
antibodies against IκB and NF-κB p65, followed by Alexa 
Fluor 555 goat anti-mouse IgG and and Alexa Fluor 488 goat 
anti-rabbit IgG. Nuclei were stained with DAPI (blue). Red, 
IκB; green, NF-κB. Immunofluorescence pictures of two 
independent experiments are shown. 
Figure 4.12: Effects of archazolid B on 
transcription factors STAT1 and STAT3. 
Macrophages were pre-incubated with 
archazolid (Arc B) at the indicated 
concentrations, with parthenolide (10 µM) 
or with vehicle (0.1% DMSO) for 16 h and 
stimulated with LPS (100 ng/mL) for 15 min 
or left untreated. Protein phosphorylation or 
expression in cell lysates were analyzed by 
Western blotting. Representative Western 
blots of two to four independent experiments 
are shown. β-Actin was used as control.
Values shown are percentages of vehicle 
control, means + SEM; n = 2-4 (upper left 
panel); n = 3 (upper right panel); n = 3-4 
(lower left panel); n = 3 (lower right panel).
**P < 0.01, vs. the LPS-stimulated vehicle 
(DMSO). ANOVA + Bonferroni post-hoc 
test. 
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10 nM elevated phosphorylation of STAT1 in LPS/IFN-γ-stimulated macrophages it did not 
strongly affect STAT3 in M1 and decreased both transcription factors in IL-4-stimulated cells 
slightly (Figure 4.12). 
 Kinases involved in LPS signal transduction 
Because archazolid obviously stimulated the LPS-induced increase of TNFα levels, it seemed 
possible that archazolid may enhance the involved signal transduction. Thus, the phosphorylation 
of typical protein kinases (PK) that are integrated in the signal transduction was analyzed by 
Western blotting. Macrophages, starved for 6 h by serum depletion prior to LPS activation, were 
treated with or without archazolid and then stimulated with LPS for 15 min. Reference PK 
inhibitors were used to control kinase-specific protein phosphorylation. Archazolid (10 and 100 
nM) did not affect the phosphorylation/activation of Akt, ERK, p38 MAPK, and MEK1/2 (Figure 
4.13). Though, SAPK/JNK was increased by archazolid as well as MEK-3/6, which was, however, 
Figure 4.13: Macrophages, starved for 
6 h prior to LPS-stimulation, were pre-
incubated with archazolid (Arc B) at 
indicated concentrations, with reference 
inhibitors (LY294002 (10 µM), U0126 
(3 µM), SB203580 (10 µM), SP600125 
(10 µM)) or with vehicle (0.1% DMSO) 
for 16 h and stimulated with LPS 
(100 ng/mL) for 15 min or left untreated. 
Protein phosphorylation or expression in 
cell lysates were analyzed by Western 
blotting. Representative Western blots of 
three to five independent experiments are 
shown. The respective unphosphorylated 
protein or GAPDH were used as control. 
Values shown are percentages of vehicle 
control, means + SEM; n = 3 (MEK3/6,
ERK, SAPK/JNK, Akt); n = 5 (p38, 
MEK1/2). *P < 0.05, **P < 0.01, vs. the 
LPS-stimulated vehicle (DMSO). ANOVA 
+ Bonferroni post-hoc test. 
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not elevated as strong as this resulted in an induction of its downstream kinase p38. The reference 
inhibitors (LY294002 for Akt, U0126 for ERK, SB203580 for p38 and SP600125 for SAPK/JNK) 
blocked phosphorylation as expected (Figure 4.13). 
 ROS levels 
Production of ROS represents a characteristic property of M1 phenotypes due to their important 
role as phagocytic cells as an important step in innate immunity defending the host against 
invading pathogens. After revealing archazolid as compound elevating NF-κB activity therefore 
increasing TNFα levels in LPS and LPS/INF-γ stimulated macrophages, it was further examined 
if archazolid contributes to elevated ROS levels in LPS-stimulated macrophages. At 
concentrations of 10 and 30 nM archazolid increased ROS levels significantly (Figure 4.14) 
whereas the NADPH oxidase inhibitor DPI [250] diminished ROS formation. 
 Viability of MDA-MB-231 
Although archazolid exhibits potent cytotoxic activity against cancer cells, we demonstrated that 
the viability of monocyte-derived macrophages, regardless of their polarization state, is not 
impaired by archazolid (4.1.2, Figure 4.3). There is evidence that high TNFα levels contribute to 
elimination of tumor cells [9]. After we had revealed that archazolid increases TNFα release from 
LPS- and LPS/IFN-γ-activated macrophages, it was interesting to investigate whether supernatants 
of archazolid treated macrophages decrease the viability of the cancer cell line MDA-MB-231 due 
to high content of TNFα. Macrophages were pre-treated with archazolid (10 nM and 100 nM) for 
30 min and stimulated with LPS for 4 h. In order to avoid that archazolid directly decreases 
viability of the cancer cell line, the medium was changed to wash out archazolid and macrophages 
Figure 4.14: ROS levels in LPS-stimulated macrophages. 
Macrophages were pre-incubated with archazolid (Arc B) at the 
indicated concentrations, DPI (5 µM), or with vehicle 
(0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) 
for 24 h. Fluorescence of oxidized DCFH-DA (5 µg/mL) was 
measured (excitation wavelength: 485 nm, emission 
wavelength: 535 nm). Values shown are percentages of vehicle 
control, means + SEM; n = 4. *P < 0.05, ***P < 0.001 vs. the 
LPS-stimulated vehicle (DMSO). ANOVA + Tukey post-hoc test.
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were further incubated for 20 h. The viability of MDA-MB-231 after treatment with prepared 
supernatants for 48 h was determined by MTT assay. Indeed, supernatants of macrophages treated 
with 100 nM archazolid reduced the viability of MDA-MB-231 significantly (10 nM: 80% ± 3%; 
100 nM: 42% ± 6%) (Figure 4.15). However, abolishing the effects of supernatants of archazolid-
treated cells by a TNFα antibody could not be achieved, supposing that decreased viability of 
MDA-MB-231 is not only due to elevated TNFα levels. 
4.3 Influence of archazolid on eicosanoid metabolism 
 COX-2 products 
Besides cytokines, the eicosanoids are prominent mediators linked to inflammation and ITC. Thus, 
archazolid was investigated to see if it also modulates lipid mediator formation. Macrophages were 
pre-incubated with archazolid and stimulated with LPS, LPS/IFN-γ, or with IL-4 for 24 h and 
PGE2 release into the medium was assessed by ELISA. Dexamethasone, a potent anti-
inflammatory drug that was shown to suppress PGE2 release in activated macrophages [251, 252] 
was used as reference compound. Surprisingly, archazolid (1 to 100 nM) affected PGE2 in the 
different macrophage phenotypes in a distinct manner, depending on the polarization. Thus, in 
LPS- and LPS/INF-γ-stimulated macrophages, archazolid concentration-dependently increased 
PGE2 up to 2.3-fold (Figure 4.16, a and b) whereas in M2 cells, PGE2 levels were not altered 
(Figure 4.16, c). A similar pattern was observed for the v-ATPase inhibitors bafilomycin and 
apicularen that also significantly upregulated PGE2 levels at 10 to 100 nM in M and M1 but not in 
M2 cells (Figure 4.16, d-f). 
Figure 4.15: Viability of MDA-MB-231 after incubation with 
archazolid-treated macrophage supernatants. MDA-MB-231 were 
pre-incubated with staurosporine (stauro; 3 µM) for 30 min and 
stimulated with LPS (100 ng/mL) or incubated with macrophage 
supernatants (pre-treated with archazolid (Arc B; 100 nM), 
dexamethasone (Dex; 1 µM), TNFα antibody (1 µg/mL) with or 
without archazolid (Arc B; 100 nM) or vehicle (0.1% DMSO)) for 
48 h. Cell viability determined by MTT assay. Values shown are 
percentages of vehicle control, means + SEM; n = 3-5. ***P < 
0.001 vs. the LPS treated vehicle (DMSO). ANOVA + Bonferroni 
post-hoc test. 
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Besides PGE2, other prostanoids are produced by the COX pathway in macrophages [253]. In 
order to investigate whether v-ATPase inhibition is attributable to COX-2 induction the formation 
of other prostanoids (PGF2α, TxB2, 12-HHT and 11-HETE) was examined using UPLC-MS/MS 
analysis. Though the magnitudes of all these produced prostanoids were different, the enhancing 
Figure 4.16: Effects of v-ATPase inhibitors on PGE2 levels. Macrophages were pre-incubated with archazolid 
(Arc B), apicularen (Apic A), bafilomacin (Baf A1) at indicated concentrations, dexamethasone (Dex; 1 µM), or with 
vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL), LPS (100 ng/mL)/IFN-γ (100 ng/mL) or IL-4 
(20 ng/mL) or left unstimulated for 24 h. PGE2 release into supernatants of macrophages was analyzed by ELISA. (a) 
Absolute value of 100% control: 1248 ± 451 pg/mL, (b) absolute value of 100% control: 767 ± 391 pg/mL, (c) absolute 
value of 100% control: 732 ± 246 pg/mL. (d) absolute value of 100% control: 1366 ± 503 pg/mL, (e) Absolute value 
of 100% control: 1248 ± 451 pg/mL, (f) absolute value of 100% control: 1563 ± 167 pg/mL. Values shown are 
percentages of vehicle control, means + SEM; n = 3-4. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS, LPS/IFN-
γ or the IL-4-stimulated vehicle (DMSO), respectively. ANOVA + Tukey post hoc test (a-c), ANOVA + Bonferroni 
post hoc test (d-f). 
a b 
c d 
e f 
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effect of archazolid (100 nM) on prostanoid mediators was obvious (Figure 4.17). PGF2α and TxB2 
were increased by about 1.5-fold whereas 12-HHT and 11-HETE were increased about 2.2- and 
3.3-fold, respectively. The differences between LPS and LPS/IFN-γ stimulation were only small 
but surprisingly, except for 12-HHT, LPS stimulation led to higher product formation than its 
combination with IFN-γ. 
 pH-elevating drugs 
Blocking the acidification of vesicles and certain organelles [254, 255], it appeared possible that 
alterations in the vesicular pH by v-ATPase inhibitors, especially an elevation, may underlie the 
upregulation of PGE2 in M1. Macrophages pre-incubated with archazolid or agents that also 
elevate the vesicular pH by other mechanisms such as chloroquine or NH4Cl were stimulated with 
either LPS or LPS/INF-γ for 24 h. The release of PGE2 into supernatants was examined by ELISA. 
However, contrarily to archazolid the pH elevating drugs chloroquine and NH4Cl did not increase 
but markedly reduced PGE2 synthesis in M and M1 (Figure 4.18). 
Figure 4.17: Effect of archazolid on COX-2 product 
formation. Macrophages were pre-incubated with 
archazolid (Arc B; 100 nM) or with vehicle 
(0.1% DMSO) for 30 min and stimulated with LPS 
(100 ng/mL), LPS (100 ng/mL)/IFN-γ (100 ng/mL) or 
IL-4 (20 ng/mL) for 24 h. Levels of COX-2 products were 
analyzed by UPLC-MS/MS. Values shown are 
percentages of vehicle control, means + SEM; n = 3-4. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS, 
LPS/IFN-γ or the IL-4-stimulated vehicle (DMSO), 
respectively. Paired t-test. 
Figure 4.18: Effect of pH elevation on PGE2 release. 
Macrophages were pre-incubated with archazolid (Arc B; 
10 nM), chloroquine (CQ; 100 µM), NH4Cl (50 mM) or vehicle 
(0.1% DMSO) for 30 min and stimulated with LPS 
(100 ng/mL)/IFN-y (100 ng/mL) or left unstimulated for 24 h. 
PGE2 release into supernatants of macrophages was analyzed by 
ELISA. Values are shown as percentages of vehicle control, 
means + SEM; n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs. the 
LPS or LPS/IFN-γ stimulated vehicle (DMSO), respectively. 
ANOVA + Bonferroni post-hoc test. 
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 Arachidonic acid release 
v-ATPase inhibitors may directly interact with the enzymes involved in PG synthesis including 
cPLA2. Although there is no direct stimulatory effect of archazolid on cPLA2 in cell-free assays 
[256], it appeared possible that v-ATPase inhibitors could activate the enzymes by direct 
interference in the cellular environment. Macrophages were first stimulated with LPS for 24 h and 
then labeled with [3H]-AA for 24 h. Macrophages were pre-incubated with archazolid or the cPLA2 
inhibitor RSC-3388 for 10 min before thiomersal was added for 5 min to reduce re-acylation of 
unconverted AA into membranes. Then, cells were stimulated with Ca2+-ionophore A23187 for 
AA release by cPLA2 for 30 min. In such short-term incubation, archazolid (up to 100 nM) failed 
to modulate AA release, and RSC-3388 suppressed AA liberation as expected (Figure 4.19). 
 COX-2 activity, protein-, and mRNA expression 
Having determined that cPLA2 activity and thus substrate supply is not influenced by archazolid 
the possibility remained that the v-ATPase inhibitor affects enzymes downstream of cPLA2 as 
COX-2 directly. To analyze COX-2 activity by short term incubation, macrophages were first 
stimulated with LPS or LPS/IFN-γ for 24 h to induce enzyme expression. Then, cells were pre-
incubated with archazolid (100 nM) or the COX inhibitor indomethacin (10 µM) for 15 min and 
stimulated with Ca2+-ionophore A23187 plus AA for 30 min. The short-term PGE2 synthesis was 
increased only marginal in LPS-stimulated but was rather slightly reduced in LPS/IFN-γ-
stimulated macrophages by archazolid whereas indomethacin reduced PGE2 synthesis as expected 
(Figure 4.20). This finding rather excludes direct stimulatory effects of archazolid on COX and 
PGE synthases. 
Figure 4.19: Effect of archazolid on AA release. Macrophages were 
stimulated with LPS (100 ng/mL) for 24 h before labeling with [3H]AA for 
24 h. Cells were pre-incubated with archazolid (Arc B) at indicated 
concentrations, RSC-3388 (1 µM) or vehicle (0.1% DMSO) for 10 min, 
thiomersal (50 µM) was added for 5 min and cells were stimulated with 
A23187 (2.5 µM) for 30 min. [3H]AA release was analyzed by scintillation 
counting. Values are shown as percentages of vehicle control, means + 
SEM; n = 2. 
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Next, the protein expression of COX-2 in LPS-stimulated macrophages with respect to its 
influence by archazolid was investigated. Macrophages were pre-treated with archazolid (10 and 
100 nM) or dexamethasone, activated by LPS, and COX-2 protein was assessed by Western blot. 
As depicted in Figure 4.21, the amounts of COX-2 protein were increased by archazolid at 100 
nM. Dexamethasone (1 µM) repressed COX-2 expression as expected and also prevented the 
increased levels of COX-2 due to archazolid (Figure 4.21) shown by co-incubation of both 
substances. 
Since dexamethasone blocks COX-2 induction on the transcriptional level [257, 258], it appeared 
reasonable to study the effects of archazolid on the COX-2 mRNA level. Macrophages were pre-
incubated with archazolid with or without dexamethasone and stimulated with LPS for 1, 4, 8, 16, 
20, and 24 h. In fact, archazolid (100 nM) caused a continuous elevation of COX-2 mRNA relative 
to B2M and β-actin as housekeeping genes with a maximum at 20 h and an 7-fold elevation (Figure 
4.22, A). Of interest, this upregulatory effect of archazolid was completely repressed by 
dexamethasone (Figure 4.22, A) in agreement with PGE2 release (Figure 4.22, B). 
Figure 4.20: Effect of archazolid on COX-2 activity. Expression of 
COX-2 in macrophages was initiated by stimulation of the cells with 
LPS (100 ng/mL) or LPS (100 ng/mL)/IFN-γ (100 ng/mL) for 
24 h. Macrophages were pre-incubated with archazolid (Arc B; 
100 nM), indomethacin (Indo; 10 µM) or vehicle (0.1% DMSO) for 
15 min and stimulated with A23187 (2.5 µM) plus AA (5 µM) for 
30 min. PGE2 in supernatants was measured by ELISA. Data in is 
shown as percentages of vehicle control, means + SEM; n = 3. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. the LPS or LPS/IFN-γ 
stimulated vehicle (DMSO), respectively. ANOVA + Bonferroni post-
hoc test. 
Figure 4.21: Cells were pre-incubated with archazolid (Arc B) at indicated concentrations with or without 
dexamethasone (Dex; 1 µM) or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h.
COX-2 protein in macrophage lysates was analyzed by Western blotting. Representative Western blots of three
independent experiments are shown. β-Actin was used as control. 
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 Lipoxygenase product formation 
Macrophages express various LOs (5-LO, 12-LO and 15-LO) that in analogy to COX enzymes 
convert AA via dioxygenation to bioactive lipid mediators (e.g., LTs, 5/12-DiHETEs, 5-HETE, 
12-HETE and 15-HETE) [89, 105]. Thus, the supernatants of M, M1 and M2 were also analyzed 
for LO-derived mediators using a UPLC-MS/MS technique. Similar to the prostanoids, the 15-
LO-derived product 15-HETE was strongly upregulated by 10 and 100 nM archazolid in M and 
M1 cells, but not in M2 (Figure 4.23, A). 12-LO product synthesis was not altered by the v-ATPase 
inhibitor (Figure 4.23, B). In contrast to the prostanoids and 15-HETE, the synthesis of 5-LO-
derived products (5-HETE, LTB4 and its two trans-isomers) were clearly reduced by 10 nM 
archazolid in all three types of macrophages (M, M1, M2) with prominent effects in M1 and M2 
and less pronounced suppression in M (Figure 4.23, C). BWA4C, a well-known iron ligand-type 
5-LO inhibitor [259], was used as reference substance which blocked 5-LO product formation as 
expected almost at the level of macrophages lacking stimulation with Ca2+-ionophore A23187. 
Figure 4.22: Effect of archazolid on COX-2 mRNA expression. Macrophages were pre-incubated with archazolid 
(Arc B; 100 nM) for 30 min or with archazolid (Arc B; 100 nM) plus dexamethasone (Dex; 1 µM) for 16 h or with 
vehicle (0.1% DMSO) and stimulated with LPS (100 ng/mL) for indicated times. mRNA was extracted and determined 
by RT-qPCR. mRNA levels were normalized against geometric mean of B2M and β-Actin. PGE2 in supernatants after 
16 h pre-incubation and 24 h stimulation with LPS (100 ng/mL) were analyzed by ELISA. Values shown are given as 
fold increase of LPS-treated cells (no archazolid) (A) or as percentages of vehicle control (B), means + SEM; n = 3. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. the unstimulated archazolid B treated sample (A) or vs. the LPS-stimulated 
vehicle control (B). ANOVA + Tukey post-hoc test. 
A B 
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Beyond this, v-ATPase inhibition by apicularen and bafilomycin was also shown to impair 5-LO 
product formation (Figure 4.23, D). 
A 
B 
C 
D 
Figure 4.23: Effect of v-ATPase inhibition on lipoxygenase product formation. Macrophages were pre-incubated 
with archazolid (Arc B) at indicated concentrations, apicularen (Apic A; 100 nM), bafilomycin (Baf A1; 100 nM), 
BWA4C (100 nM), or vehicle (0.1% DMSO) for 30 min and stimulated with either LPS (100 ng/mL), LPS (100 
ng/mL)/IFN-γ (100 ng/mL) or IL-4 (20 ng/mL) for 24 h. Cells were stimulated with A23187 (2.5 µM) for 10 min. 
Levels of 5-LO products (5-HETE, LTB4, epi/trans- LTB4), 12-HETE and 15-HETE were analyzed by UPLC-MS/MS. 
Values shown are percentages of vehicle control, means + SEM. n = 3-8. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
the LPS, LPS/IFN-γ or the IL-4-treated vehicle (DMSO). ANOVA + Tukey (archazolid B) or Bonferroni (apicularen 
A, bafilomycin A1) post-hoc test. 
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By analysis of 5-LO products derived from other fatty acids than AA, such as EPA-derived 5-
HEPE and DGLH-derived 5-HETrE, it should be emphasized that their formation was inhibited 
by archazolid (10 and 100 nM), too (Figure 4.24) 
4.3.5.1 5-LO translocation 
To investigate whether an impaired 5-LO translocation or deficient colocalization of 5-LO with 
FLAP is the reason for inhibited 5-LO product synthesis immunofluorescence microscopy 
experiments were conducted. 5-LO predominated in the nucleoplasm in unstimulated 
macrophages (Figure 4.25, upper series) and translocated to the nuclear envelope upon Ca2+-
ionophore stimulation (Figure 4.25, middle series) whereas FLAP did not change its localization 
at the nuclear membrane upon stimulation. The overlay of 5-LO and FLAP in Ca2+-ionophore 
stimulated- and archazolid-treated macrophages (Figure 4.25, lower panel) shows that the v-
ATPase inhibitor does not disturb 5-LO translocation to the nuclear membrane. 
Figure 4.24: Effect of archazolid on ETA- and EPA-derived 5-LO products. Macrophages were pre-incubated with 
archazolid (Arc B) at indicated concentrations, BWA4C (100 nM), or vehicle (0.1% DMSO) for 30 min and stimulated 
with either LPS (100 ng/mL), LPS (100 ng/mL)/IFN-γ (100 ng/mL) or IL-4 (20 ng/mL) for 24 h. Cells were stimulated 
with A23187 (2.5 µM) for 10 min. Levels of 5-HEPE and 5-HETrE were analyzed by UPLC-MS/MS. Values shown 
are percentages of vehicle control, means + SEM. n = 4. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS, 
LPS/IFN-γ or the IL-4-treated vehicle (DMSO). ANOVA + Tukey post-hoc test. 
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 5- and 15-LO product formation in cell homogenates 
Since archazolid obviously affected 5- and 15-LO product formation quite differently it was 
investigated whether archazolid influences 5- or 15-LO product formation also in homogenates of 
M1 and M2 macrophages. Archazolid inhibited 5-LO product formation in homogenates of M1 
and M2 (Figure 4.26). These results regarding 5-LO product synthesis are in agreement with the 
finding that archazolid directly inhibits 5-LO in a cell-free assay [256]. 15-HETE derived from 
15-LO was increased in M1 in accordance with the increased product levels in the supernatants of 
Figure 4.25: Effect of archazolid on 5-LO 
translocation. Macrophages were pre-incubated with 
archazolid (Arc B; 100 nM) or vehicle (0.1% DMSO) 
for 16 h and stimulated with A23187 (2.5 µM) for 
3 min. Macrophages were fixed, permeabilized and 
incubated with antibodies against 5-LO and FLAP, 
followed by Alexa Fluor 488 goat anti-rabbit IgG and 
Alexa Fluor 555 goat anti-mouse IgG. Red, 5-LO; 
green, FLAP. Immunofluorescence pictures of two 
independent experiments are shown. 
Figure 4.26: Effects of archazolid on 5- and 15-LO product formation of M1 and M2 homogenates. Macrophages
were pre-incubated with archazolid (Arc B) at indicated concentrations for 30 min and polarized with LPS 
(100 ng/mL)/IFN-y (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. Cells were disrupted by sonification and CaCl2
(2 mM) and AA (20 µM) were added for 15 min. Product formation was analyzed by UPLC-MS/MS. Values shown 
are percentages of vehicle control, means + SEM. n = 3-4. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the LPS/IFN-γ 
or the IL-4-treated vehicle (DMSO). ANOVA + Bonferroni post-hoc test. 
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archazolid-treated intact cells. However, 15-HETE formation was decreased in homogenates of 
M2 macrophages (Figure 4.26) whereas 15-HETE release from intact M2 was not affected (Figure 
4.23, A, lower panel). 
 5-LO protein expression 
Having revealed that archazolid exhibits a direct inhibitory action on 5-LO, it was analyzed by 
Western blotting if archazolid influences the protein expression levels of this enzyme leading to 
decreased 5-LO product formation. As depicted in Figure 4.27 archazolid neither had an effect on 
5-LO protein expression in M1 nor in M2. 
 
Figure 4.27: Effect of archazolid on 5-LO protein expression.
Macrophages were pre-incubated with archazolid (Arc B) at 
indicated concentrations or vehicle (0.1% DMSO) for 30 min and 
stimulated with LPS (100 ng/mL)/IFN-y (100 ng/mL) or IL-4 
(20 ng/mL) for 24 h. Protein expression in cell lysates were 
analyzed by Western blotting. Representative Western blots of four
independent experiments are shown. β-Actin was used as control. 
Values shown are percentages of vehicle control, means + SEM; 
n = 2-4. 
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5 DISCUSSION 
The inflammatory status after infection or tissue injury is determined by the immune cells present 
at the inflammatory site as well as by their mediators responsible for the progression or resolution 
of inflammation [17]. Cytokines, chemokines and AA metabolites are among the most important 
molecules in this context [17, 260]. The failure of initiating the resolution phase and consequent 
progression of chronic inflammatory processes facilitate many secondary diseases, including 
cardiovascular and renal diseases, rheumatoid arthritis, atherosclerosis, and cancer [28, 261]. In 
this study, the focus was placed on inflammation-triggered cancer (ITC), where the decisive 
implication of the above-mentioned mediators has been reported before [26]. Among the innate 
immune cells involved in regulating the inflammatory environment, macrophages play a key role 
in ITC due to their marked plasticity occurring as M1 or M2 phenotype that suppress or promote 
tumor cells by modulating the immune response, respectively [157]. Affecting the synthesis or 
release of mediators from innate immune cells involved in inflammation and related diseases by 
pharmaceutical intervention might thus constitute a valuable therapeutic approach. Moreover, 
targeting TAMs or the specific modulation of mediator release from macrophage phenotypes 
might offer additional perspectives in anti-cancer therapy. Thus, it is not surprising that several 
approaches exist with this aim [184, 262-264].  
Several types of tumors overexpress the v-ATPase [220, 221] that maintains a low pH in the tumor 
microenvironment for an optimal activity of tumor promoting enzymes [223]. For this reason, the 
v-ATPase is a potential target in the treatment of cancer and the potency of selective v-ATPase 
inhibitors against several cancer cell lines has previously been reported [5, 222, 229]. 
Nevertheless, there is only little knowledge about v-ATPase inhibition in human primary cells 
[265, 266]. Thus, the question was raised whether and how the v-ATPase inhibitor archazolid B 
affects human monocyte-derived macrophages. In this respect it was of particular interest if the 
polarization state of macrophages is of relevance. Furthermore, it was important to reveal whether 
the promising effects of archazolid B on cancer cells might be supported by effects of archazolid 
B on polarized macrophages. This thesis gives insights into the effects of the v-ATPase inhibitor 
archazolid B on inflammatory cytokine release from M1 and M2, and the possible underlying 
biochemical mechanisms are discussed. Furthermore, the involvement of archazolid B in 
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eicosanoid metabolism of M1 and M2 was addressed. The relevance of these effects in view of 
ITC and possible benefits is discussed. 
5.1 Archazolid B inhibits the v-ATPase functionality by 
simultaneous unimpaired macrophage integrity 
Archazolid B is known to inhibit the v-ATPase [210] and to exhibit potent cytotoxic activity 
against several cancer cell lines [5, 267]. Thus, it was obvious and, with respect to future 
applications of the compound in anti-cancer therapies, even necessary to investigate if archazolid 
shows analogous cytotoxicity against primary human cells, especially against macrophages since 
they are important immune cells that play an essential, though diverse role in inflammation and 
ITC. The viability of macrophages differentiated from freshly isolated peripheral blood 
monocytes, stimulated with LPS alone (M), in combination with IFN-γ (M1) or with IL-4 (M2) 
was not impaired by archazolid. Also microscopic analysis supported macrophage integrity. Even 
the polarization revealed morphological differences between M/M1 and M2 since the latter were 
rather round shaped cells, whereas M/M1 exhibited a DC-like appearance, clearly intensified by 
archazolid. Whereas the morphological distinctions between M1 and M2 have already been 
observed before [268, 269], the potentiation of M1 appearance by archazolid supposes a 
polarization enhancement of the M1 phenotype. Morphological changes of activated macrophages 
is closely connected to their phagocytic activity [270] since this constitutes one of the main features 
of M1 clearing the environment both from pathogens as well as from apoptotic cells or cell debris. 
The proper engulfment of foreign particles is thus an essential event for the host’s health. 
Therefore, an unimpaired phagocytic activity after archazolid treatment further confirmed that the 
compound preserves the cellular integrity. Measuring the pH of archazolid-treated and LPS-
stimulated macrophages as well as their microscopic analysis after FITC-Dextran or LysoTracker 
incubation revealed that archazolid inhibits the v-ATPase and elevates vesicular pH as reported 
[210]. However, the impact of archazolid on cellular pH homeostasis did not impair the viability 
of M, M1 and M2 which was the indispensable basis for further investigations. 
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5.2 Archazolid elevates TNFα levels in M and M1 due to 
increased transcription 
Cytokines are intensively involved in inflammatory processes and in the communication between 
host/immune cells and neoplastic cells [8, 29]. Changes in this mediator system can result in the 
modulation of cell functionality. M1 and M2 exhibit a completely different pattern of cytokine 
expression due to distinct regulatory mechanisms according to their opposing roles in 
inflammation and cancer [150]. Different impacts of compounds on protein expression in M1 and 
M2 were therefore basically conceivable. Indeed, treatment of M1 and M2 with archazolid differed 
between the two subtypes in regard to their cytokine release. Pro-inflammatory IL-1, IL-6, IL-8, 
MCP-1, TNFα, and anti-inflammatory IL-10 release from M2 were not affected by archazolid but 
a selective elevation of TNFα release from M1 was achieved at nanomolar concentrations. TNFα 
release from M was increased with similarly intensity, supposing a specific effect of archazolid on 
the pro-inflammatory macrophage phenotype. The increase of TNFα levels was furthermore 
revealed as a class effect of v-ATPase inhibiting agents since apicularen and bafilomycin affected 
M and M1 in the same manner, whereas they did not influence M2 cytokine levels. The v-ATPase 
functions mainly in regulating organellar pH, an essential requirement of the cell [191]. In fact, 
vesicular acidification is an important procedure for intracellular trafficking due to the pH gradient 
along the endo- and exocytic pathway that determines the cargo’s way in the cell [271]. v-ATPase 
inhibition by archazolid was therefore reasonable to be involved in elevating TNFα levels in M 
and M1. However, opposite data with other pH elevating drugs such as ammonium chloride and 
chloroquine, which did not increase TNFα levels but rather decreased TNFα release from M and 
M1 excluded pH increases as a major cause. Apart from the fact that the cytokine profile of M1 
includes TNFα, this cytokine further belongs, next to LPS and INF-γ, to the cytokines which 
induce the polarization of macrophages towards M1 [151]. Therefore, the strong increase of TNFα 
levels from M1 by archazolid might affect phenotypic development of macrophages in the sense 
of a positive feedback. 
Tracing back the increased release of TNFα, modifications in transcriptional or translational 
processes are possible, particularly since transcription is a prominent step in gene regulation, 
controlled by a variety of transcription factors [272]. TNFα mRNA expression was found to be 
significantly increased by archazolid, apparently leading to elevated protein levels. In contrast, IL-
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1β mRNA expression was not affected in accordance with protein levels after archazolid treatment, 
affirming a specific effect of archazolid on TNFα mRNA. The assumption of transcription factors 
being involved in elevating TNFα mRNA by archazolid was further supported by the result of the 
co-incubation of archazolid with dexamethasone, which showed that elevated TNFα mRNA by 
archazolid can be repressed by dexamethasone. The ability of dexamethasone to regulate gene 
transcription has been attributed to the interference of its glucocorticoid receptor with different 
transcription factors, such as NF-κB [258]. Members of the “kB”-family seem to be the most 
prominent enhancers for transcriptional activation of the TNFα gene [273, 274]. NF-κB mediates 
its effects by binding specific elements in the promoter region of the DNA, for instance of the 
TNFα gene, to regulate transcription. Therefore, it has to be transported from the cytoplasm into 
the nucleus when released from its inhibitory IκB proteins [50]. The proper translocation of NF-
κB p65 upon stimulation by simultaneous degradation of IκB, also after archazolid treatment, was 
shown by immunofluorescence microscopy. Immunoblotting revealed an elevated activation of 
NF-κB p65 by archazolid. Unexpectedly, however, IκB phosphorylation remained unaffected. A 
possible explanation for this might base on the finding that phosphorylation at serine 536 of p65 
can occur IκB-independent [275] and the antibody used in this study for immunoblotting detected 
phosphorylated p65 at Ser536. Additionally, it was found that full activity of NF-κB does not 
necessarily need degradation of IκB, but instead post-translational modifications such as 
phosphorylation at specific residues [53]. Phosphorylation at Ser536, located in the transactivation 
domain (TAD) of p65, usually takes place by IKK (α, β or ε), that are also activated by LPS, TNFα, 
AKT, p38, or directly by the NF-κB-activating kinase (NAK) [53]. Alternatively, phosphorylation 
at Ser536 is achieved by the ribosomal subunit kinase (RSK)-1. The latter acts through signaling 
by the tumor suppressor p53 which represents the pathway independent from IκB degradation and 
increases NF-κB binding to the target DNA due to decreased IκB affinity [276] (Figure 5.1). An 
activation of NF-κB via TNFα as stimulatory agent is also possible [277]. However, it could be 
excluded that elevation of TNFα levels by archazolid caused the increase of NF-κB activity, since 
NF-κB phosphorylation was already elevated by archazolid after 15 min whereas increased TNFα 
release by the compound was first obtained between four and eight hours, further increasing up to 
24 hours. Thus, the exact mechanisms of NF-κB induction by archazolid could not be fully 
elucidated but an involvement of the pathways of IKK, or RSK-1 seem to be reasonable. 
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Upon transcription, the RNA transcripts have to be transported from the nucleus to the cytoplasm 
for translation and post-translational modifications in the ribosomes at the ER and the Golgi. 
Concerning this, the stability of the transcribed mRNA is a further crucial step within de novo 
protein biosynthesis since stabilizing mechanisms might lead to a higher translation rate, resulting 
in elevated protein levels. Archazolid, however, did not impair degradative processes, and 
enhanced stability was thus not implicated in the elevation of TNFα levels. 
The activation of transcription factors is regulated by upstream signaling pathways, where three 
prominent MAPK pathways are intensively involved in the regulation of TNFα release from 
human cells, namely the ERK, the p38 MAPK, and the SAPK/JNK pathway [38, 40, 41, 278], 
therefore, representing possible targets for archazolid. The activation of the three MAPKs is 
induced by LPS in accordance with the effect of archazolid on TNFα release. However, 
phosphorylation of MEK1/2 as well as its downstream target ERK1/2 were not affected by 
archazolid. Activation of MEK3/6 was slightly elevated by the compound but did not result in 
further activation of p38 MAPK. Accordingly, it is unlikely that MEK3/6 activation causes 
increased TNFα levels. Phosphorylation of SAPK/JNK was elevated by archazolid and might 
Figure 5.1: Simplified schematic depiction of induction of NF-κB activity resulting in elevated TNFα gene 
transcription. NF-κB activity is elevated by phosphorylation of Ser536 in the TAD of p65 achieved by p53-dependent 
RSK-1 or IKK that are activated by NAK or signaling through LPS, TNFα or Akt/p38. Transcriptional activity of NF-
κB can additionally be induced by interference of JNK-activated AP-1. NAK, NF-κB-activating kinase; IKK, IκB 
kinase; RSK-1, ribosomal subunit kinase-1; AP-1, activator protein-1; RHD, Rel homology domain; TAD, 
transactivation domain. 
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therefore contribute to elevated TNFα levels in LPS-stimulated macrophages particularly since 
this kinase has been reported to regulate TNFα synthesis [38]. However, SAPK/JNK 
phosphorylation results rather in transcriptional activation of its main target activator protein (AP)-
1 or members of the ATF, Ets, or Jun transcription factor families [279]. Though, phosphorylation 
of AP-1 positively regulates NF-κB’s transcriptional activity [51] and might therefore indeed 
contribute to elevated TNFα levels via transcriptional interaction with NF-κB (Figure 5.1). 
The kinase Akt has been found to be an oncogenic kinase in many cancers supporting survival 
mechanisms of tumor cells [49]. Furthermore, it is also implicated in cytokine synthesis [36] and 
contributes to an elevated NF-κB activity by phosphorylation of IKK in a p38 MAPK-dependent 
manner [280]. Since archazolid did not increase p38 MAPK activation it was not surprising that 
also Akt phosphorylation remained completely unaffected, supposing that elevated NF-κB 
phosphorylation as well as increased TNFα levels result from another pathway. 
Apart from their pro-inflammatory properties, or even due to them, respectively, M1 are effective 
in building immune responses against pathogens but also exhibit tumor cell killing properties 
[157]. Responsible for this is the cytokine profile, high antigen presenting activity, and the 
production of toxic intermediates, as well as all factors that affect those indirectly via diverse 
signaling pathways. By selectively increasing TNFα release from M1, archazolid becomes an 
interesting compound in the strategy of promoting M1 functions to support anti-cancer treatments. 
Even more, since archazolid itself is known to exhibit potent cytotoxic effects on tumor cells [213] 
while not decreasing viability of human primary macrophages. Promotion of polarization of host 
macrophages towards M1 might thus be a promising strategy to further potentiate the efficiency 
of archazolid against cancer cells. To substantiate the assumption that archazolid promotes M1-
related functionalities, the next step of this thesis was to investigate whether further relevant factors 
are affected by archazolid. Thus, the STAT proteins STAT1 and STAT3 were interesting proteins 
in this context due to their different roles in tumor interference [281]. As transcription factors that 
mediate cytokine and growth factor receptor signals to the nucleus they are relevant to M1/M2 
polarization. An overexpression of STAT3 has been correlated to some types of tumors, promoting 
proliferation and survival, consistent with the properties of the tumor-infiltrating M2 phenotype 
[282]. Moreover, STAT3 inhibits anti-tumor immune responses, partly mediated by NF-κB [281]. 
Contrarily, activity of STAT1 has been rather attributed to an inhibition of cancer cell growth by 
enhancing the anti-tumor immunity [281, 282] that is typical for the M1 phenotype [7]. The activity 
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of STAT1 was elevated by archazolid in M1, whereas phosphorylation of STAT3 was slightly 
repressed. In M2, the activity of both transcription factors was slightly decreased by the compound. 
Thus, at least increased activity of STAT1 in M1 by archazolid further supports the hypothesis of 
its M1-promoting activity. 
ROS are an effective tool of macrophages to defend the host against infectious pathogens [155]. 
Regarding tumor cells, the role of ROS is much more complicated, similar to the complex role of 
macrophages in cancer occurrence. There is evidence, that the presence of ROS can have tumor 
promoting effects but likewise, oxidative stress can also help to destroy cancer cells and is thus 
used in anti-cancer therapies [283]. This is due to the ability of the tumor to develop regulatory 
mechanisms which shield cancer cells from the destructive properties of ROS. However, if this 
sensitive balance is disturbed, for instance due to an excessive elevation of ROS, tumor cells will 
become sensitive to ROS and undergo ROS-induced apoptotic cell death [284] because of cell 
damage as a result of oxidized cellular proteins, lipids and nucleic acids [285]. ROS further cause 
DNA damage and participate in several signaling pathways leading to programmed cell death 
[270]. Generally, basal ROS levels of M1 exceed those of M2 [286]. Archazolid additionally 
increased ROS levels of LPS-activated macrophages which further supports the presumption of a 
promoted M1 phenotype by the v-ATPase inhibitor. ROS are produced from at least three different 
sources: during respiration in the mitochondria [287], by NADPH oxidases [288], and by several 
other enzymes, including lipoxygenases and cyclooxygenases [289]. Since TNFα activates 
NADPH-oxidases by different mechanisms [289], increased ROS levels might result from elevated 
TNFα levels after archazolid treatment. 
There are several indicators for archazolid promoting an M1 phenotype by enhancing individual 
functionalities of this macrophage subtype with respect to its immunological properties that help 
to fight against host-destructing factors like cancer cells. In view of the reported ability of 
archazolid to directly eliminate tumor cells, this additional and beneficial effect on primary 
macrophages of the M1 phenotype has to be taken into account when using v-ATPase inhibiting 
agents as anti-cancer drugs. 
To verify if elevated TNFα levels by archazolid would be able to decrease viability of cancer cells 
as assumed, a wash-out experiment was performed. Due to the compound’s property to kill tumor 
cells it had to be washed out in order to avoid that remaining archazolid falsify the result. For the 
viability test, the cancer cell line MDA-MB-231 was used. In fact, the viability of MDA-MB-231 
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was reduced by the archazolid-pre-treated samples. However, using a TNFα antibody, these effects 
could not be revoked, supposing that besides TNFα the viability of MDA-MB-231 was reduced 
by additional mechanisms. 
5.3 Enzymes of the eicosanoid metabolism are differently 
affected by archazolid 
The arachidonic acid-derived eicosanoids play a similar diverse role in inflammation as the 
cytokines since they contribute to the initiation of acute inflammation as well as to the resolution 
phase [290], therefore playing a key role in ITC. Although the v-ATPase is well-known to promote 
tumor development and inhibitors of this enzyme have been investigated in several tumor cell 
lines, studies about a possible benefit of v-ATPase inhibition in primary cells through interaction 
with the AA pathways are missing. A strong interference of archazolid with the eicosanoid 
pathway at different sites could be revealed but with completely different outcomes. PGE2 as well 
as the other COX-2-derived products PGF2α, TxB2, 11-HETE and 12-HHT were elevated 
selectively in LPS- and LPS/INF-γ stimulated macrophages by archazolid, while M2 were not 
affected. This was further independent of the used v-ATPase inhibitor since the incubation with 
apicularen and bafilomycin led to comparable results. Concerning the COX-2 products, 11-HETE 
was the metabolite with the largest increase by archazolid, but the differences between LPS and 
LPS/INF-γ stimulation are only marginal for the most metabolites. Since not only PGE2 but also 
other COX-2 products are elevated by archazolid, it can be assumed that COX-2 itself, but not 
necessarily the downstream prostanoid synthases are affected. Different intensities of increase 
might result from diverse kinetics of these terminal enzymes converting PGH2 into their products. 
COX-2 related products have long been considered only as pro-inflammatory mediators that need 
to be suppressed by potent inhibitors [291]. Nevertheless, there is increasing evidence that these 
prostanoids also mediate pro-resolving events [109] decreasing disease severity in some cases and 
that inhibition may prevent the initiation of the resolution phase [110, 114]. In view of their 
physiological diversity it is not surprising that there is more than just the role as “bad guys” in 
inflammation. Although the undisputable pro-inflammatory properties of prostanoids must not be 
disregarded, their potency in stimulating the resolution of inflammation might be exploited by 
drug intervention. With regard to M1 and the assumption that archazolid might promote this 
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phenotype in various ways as described above, the stimulation of COX-2 products further supports 
this hypothesis. 
Even though the v-ATPase has rather been related to an implication in vesicular trafficking since 
an intact pH homeostasis is relevant for the secretory pathway and PGE2 is instead released by 
passive diffusion or through the active multidrug resistance protein (MRP)-4 transporter [292], the 
contribution of pH elevation by archazolid to increased PGE2 release had to be taken into account. 
Thus, the PGE2 levels of LPS- and LPS/IFN-γ-stimulated macrophages pre-treated with 
chloroquine and ammonium chloride were measured, which emphasized an inhibition by the two 
pH elevating compounds, in contrast to the elevated PGE2 release by archazolid. Since cPLA2 
activity is pH dependent [293], a higher catalytic activity due to vesicular pH elevation resulting 
in an increased substrate supply for COX-2 may determine PGE2 synthesis. However, whereas the 
cPLA2α inhibitor RSC-3388 inhibited the release of [3H]-AA, archazolid had no effect. Equally, 
the activity of COX-2 itself was not affected by archazolid in agreement with the finding of Reker 
et al, where archazolid had only negligible effects on this enzyme at high concentrations in a cell-
free assay [256]. For this reason, protein levels in LPS-stimulated macrophages were analyzed by 
immunoblotting. COX-2 levels seemed to be relatively low compared to primary monocytes and 
were therefore hard to detect, probably attributable to a loss during the seven days lasting 
differentiation time of monocytes to macrophages. An elevation of COX-2 protein by archazolid 
at 100 nM could be shown. COX-2 expression was repressed by dexamethasone as reported [257] 
and counteracted archazolid-induced COX-2 expression. The investigation of COX-2 transcription 
further supported these results since an elevation of COX-2 mRNA was detectable after four hours 
with a maximum at 20 hours and a nearly 7-fold increase of mRNA levels. Similar to the results 
achieved for the COX-2 protein levels, dexamethasone reversed this effect completely. NF-κB 
targets COX-2 and induces COX-2 expression in macrophages in a LPS-dependent manner [294]. 
This leads to the suggestion that elevated COX-2 transcription by archazolid is the result of the 
increased activity of NF-κB by this compound. The abrogation of archazolid’s effect on COX-2 
protein and mRNA levels by dexamethasone additionally supports the involvement of NF-κB (see 
also 5.2, p. 69). 
Besides COX-2, the lipoxygenases (LOs) are prominent AA-metabolizing enzymes. However, the 
impact of archazolid on LOs was intriguingly totally different. Thus, the formation of 5-LO 
products (LTB4, epi/trans- LTB4, 5-HETE) were inhibited by archazolid in a concentration-
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dependent manner but independent of the stimulation with LPS, LPS/INF-γ or IL-4, whereby the 
strongest effect was achieved in M1. The impairment of product synthesis also in M2 was quite 
interesting since TNFα and PGE2 were only affected in the M1-like phenotypes. This was also 
found for 15-HETE, which was, in contrast to 5-LO products, increased by archazolid, but only in 
M and M1, while M2 remained unaffected. 12-LO product formation did not change by the 
influence of archazolid, neither in M and M1, nor in M2. Shifting the AA metabolism in favor of 
the COX pathway by inhibiting 5-LO as it has been reported for the reverse case [295] seems to 
be unlikely since the difference of COX-2 effects between M1 and M2 are not explainable in this 
way. Since sufficient substrate supply by cPLA2 for AA-converting enzymes was already 
investigated in the context of PGE2 formation, an impact of archazolid on cPLA2 activity could be 
excluded. Contrarily to other LOs, FLAP is only essential for the product synthesis by 5-LO, which 
requires the interaction with FLAP for full activity converting AA [126]. This is also supported by 
the finding that inhibition of FLAP by MK886 prevents leukotriene synthesis [296]. Therefore, 
the translocation of 5-LO and subsequent co-localization with FLAP was examined by 
immunofluorescence microscopy. As expected, FLAP and 5-LO did not co-localize in 
unstimulated macrophages, where 5-LO was mainly found in the nucleus, while FLAP was 
localized at the nuclear envelope. The overlay of the proteins at the nuclear membrane could be 
detected both in Ca2+-ionophore A23187-stimulated control cells as well as in archazolid-treated 
macrophages. Archazolid did therefore not result in defects of 5-LO translocation followed by 
impaired AA conversion. These results led us to investigate catalytically active 5- and 15-LO in 
cell homogenates, whereby cellular regulatory mechanisms can be excluded since in this assay 
large amounts of substrate and activity determining factors are supplied exogenously and spatial 
barriers are removed. Due to the inhibition of 5-LO products by archazolid in homogenates as 
well, it can be assumed that archazolid exhibits a direct effect on the enzyme, which is further 
supported by the impact on both macrophage subtypes. Apart from AA, 5-LO converts other fatty 
acids, such as eicosatrienoic acid (ETA, 20:3 ω-9) and eicosapentaenoic acid (EPA, 20:5 ω-3). 
Archazolid also inhibited ETA-derived 5-HETrE and EPA-derived 5-HEPE in a similar strength 
as AA-derived 5-HETE, concluding that archazolid directly interferes with 5-LO. Moreover, these 
findings are in agreement with previous studies that revealed direct inhibition of 5-LO by 
archazolid in a cell-free assay [256]. Pharmacophore studies emphasized a large compliance of 
pharmacophoric features between AA and archazolid (Figure 5.2) that could further be confirmed 
for bafilomycin and apicularen [256]. Contrarily, it was shown that the active-site pocket of COX-
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2 is too buried and narrow for archazolid to access it, which might be an explanation for the 
opposing effects found for archazolid on 5-LO and COX-2 of macrophages. To exclude the 
possibility of an effect of archazolid on protein levels of 5-LO, immunoblotting of 5-LO in M1 
and M2 was done which confirmed unaffected 5-LO expression levels. 
 
Nevertheless, homogenates of M1 and M2 revealed unexpected results regarding the product 
formation of 15-LO, namely an inhibition of 15-HETE in M2 but an increase of 15-HETE in M1, 
even though this was not as strong as in intact cells. There are reports about some differences with 
respect to the 15-LO in M1 and M2 which could give a clue for the opposing effects by archazolid. 
Examples are the higher expression of 15-LOX-2 towards 15-LOX-1 in M1 [105], the higher 
substrate specificity for AA of 15-LOX-2 [105, 297], low suicide inactivation of 15-LOX-2 [297], 
and its higher specificity for the position of oxygen insertion at C-15 [298]. Although these features 
might explain higher 15-HETE production in M1 in general (considering those, the stimulation 
with AA for 15 min taking only 15- not 12-HETE into account are adverse conditions for 15-LOX-
1), they do not reveal clear explanations for the effects achieved by archazolid. Since 5-LO 
converts 15-HETE into lipoxins and 5-LO is inhibited by archazolid, increased 15-HETE levels in 
M1 might result from an accumulation of non-transformed 15-HETE. However, 5-LO is inhibited 
in M2 as well but 15-HETE elevation could only be observed in M1. Other possibilities might 
base on 15-HETE found in some cells to be a by-product of COX and even suppressing the 5-LO 
pathway [299], or on a cross-talk between the pathways of COX and 15-LO leading to a mutual 
activation [300]. Incubation of M and M1 with the COX-inhibitor dexamethasone showed indeed 
an inhibition of 15-HETE formation, supporting the idea of COX-2 being responsible for 15-HETE 
elevation. However, inhibition of 15-HETE formation by archazolid in homogenates of M2 cannot 
Figure 5.2: Pharmacophore alignment 
of archazolid and AA. Yellow: 
hydrophobic interaction points; red: 
hydrogen-bond acceptor positions. 
Adapted from Reker et al [256].
Reprinted by permission from Macmillan 
Publishers Ltd: Nature Chemistry 6, 
1072–1078, copyright 2014. 
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be explained by 15-HETE being a by-product of COX-2 since PGE2 and other COX-2 products 
were not affected by archazolid in M2. Finally, lacking the elevating effect of archazolid on 15-
HETE in M2 might result from an increased incorporation of 15-HETE in membranes induced 
especially by IL-4 stimulation [301], resulting in less amounts of 15-HETE in supernatants of M2. 
Concluding, although there are some conceivable approaches for increased 15-HETE by 
archazolid in M1, the accompanying inhibitory effect of the compound on 15-HETE in M2 
remains incompletely understood. 
 
In conclusion, the results of this thesis show that archazolid selectively elevates TNFα release from 
LPS- and LPS/IFN-γ-stimulated macrophages whereas IL-4-stimulated macrophages remain 
unaffected. We could attribute increased TNFα levels to an elevation of transcription of TNFα by 
archazolid due to enhanced NF-kB activity. However, no effects on other investigated cytokines 
could be revealed by archazolid in neither M, M1 nor M2, which supports the selectivity of the 
compound’s effect on TNFα. As expected of a v-ATPase inhibitor, archazolid was shown to 
elevate vesicular pH but nevertheless, cell viability as well as cellular integrity of polarized 
macrophages were not impaired. This fact combined with selective TNFα elevation by archazolid 
highlights the beneficial effects in terms of cancer treatment besides purely cytotoxic effects of 
archazolid on cancer cells. Furthermore, we revealed the AA cascade as target of archazolid due 
to its various effects on involved LOs. Inhibited 5-LO product formation in polarized macrophages 
besides elevated 15-HETE production in M1 by archazolid emphasizes the relevance of the v-
ATPase in eicosanoid formation and additionally demonstrates the potential of v-ATPase 
inhibitors to promote an anti-inflammatory pro-resolving eicosanoid status. 
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